

---

ANNUAL REPORT  
2019

---

Lives Unaffected by Cystic Fibrosis

# IMPORTANT FACTS ABOUT CYSTIC FIBROSIS

## DID YOU KNOW?

YOU CANNOT CATCH CYSTIC FIBROSIS, YOU ARE BORN WITH IT.




Cystic fibrosis is classified as a chronic illness. It is not covered by the National Disability Scheme. There is no designated Government funding.



Cystic fibrosis affects the airways, lungs, endocrine system – pancreas, sweat glands and reproductive organs. Men with cystic fibrosis may experience fertility issues.



Secondary health conditions associated with cystic fibrosis but not limited to are diabetes, arthritis, cancer, liver disease and mental wellness.



ONE IN 25 AUSTRALIANS ARE CARRIERS OF THE CYSTIC FIBROSIS GENE.

In Australia, every four days a child is born with cystic fibrosis.

81% of parents were unaware they were carriers of the disease.



The average life span of a person born today with cystic fibrosis is less than 40 years. Most people do not live past their twenties.



People living with cystic fibrosis take up to 80 tablets a day to treat their condition – that's the equivalent of one bathtub a year of medication.

**Cystic fibrosis is a life-long and complex disease.**  
**There is no cure.**

# TABLE OF CONTENTS

## SECTION 1 - OVERVIEW OF CYSTIC FIBROSIS QUEENSLAND LIMITED

---

OUR MISSION .....	11
OUR VISION .....	13
OUR HISTORY .....	15
RESPONDING TO THE NEEDS OF OUR MEMBERS TODAY AND IN THE FUTURE .....	23
A MESSAGE FROM OUR QUEENSLAND PATRON .....	27
A MESSAGE FROM OUR NORTHERN TERRITORY PATRON.....	29
CHIEF EXECUTIVE OFFICER'S REPORT .....	31
BOARD CHAIR AND PRESIDENT'S REPORT .....	35
OUR PEOPLE.....	39
STRUCTURE AND MANAGEMENT .....	45

## SECTION 2 - HOW WE ARE MAKING A DIFFERENCE

---

OUR COMMUNITY.....	47
OUR PROGRAMS.....	49
CREATING A FUTURE.....	57

## SECTION 3 - ACCOUNTABILITY

---


TREASURER'S REPORT .....	65
FINANCIAL STATEMENTS.....	69
AUDITOR'S STATEMENT .....	97

## SECTION 4 - SUPPORT OUR CAUSE

---

RAISING FUNDS AND AWARENESS .....	91
PARTNERSHIPS.....	94
COMMUNITY FUNDRAISING .....	97
OUR SOCIAL ENTERPRISE .....	101
GRANTS AND MAJOR DONORS.....	105
RECOGNISING OUR VOLUNTEERS .....	109
OUR DIAMOND JUBILEE.....	111
CONTACT US .....	116

OUR COMMUNITY SHAPES  
THE PROGRAMS WE DELIVER.



CYSTIC FIBROSIS QUEENSLAND  
PROVIDES SUPPORT, SERVICES AND  
HOPE TO THOSE FIGHTING  
CYSTIC FIBROSIS.

# WHAT IS CYSTIC FIBROSIS?

---

Cystic fibrosis primarily affects the lungs and digestive systems due to an exocrine malfunction that is responsible for producing saliva, sweat, tears and mucus. There is currently no cure.



People with cystic fibrosis develop an abnormal amount of excessively thick and sticky mucus within the lungs, airways and the digestive system. This causes impairment of the digestive functions of the pancreas and traps bacteria in the lungs resulting in recurrent infections, and leads to irreversible damage. Lung failure is the major cause of death for someone with cystic fibrosis.

From birth, a person with cystic fibrosis undergoes constant medical treatments and physiotherapy.

THAT'S A BATHTUB FULL OF  
MEDICATION A YEAR.



A PERSON LIVING WITH CYSTIC  
FIBROSIS TAKES UP TO 80 CAPSULES  
A DAY.

# YOU CANNOT CATCH CYSTIC FIBROSIS

---

The cystic fibrosis gene is inherited from both parents and it can skip generations. It is autosomal recessive meaning that it occurs equally in males and females. In Australia, one in 2500 babies are born with cystic fibrosis, that's one every four days. On average one in 25 people carry the cystic fibrosis gene and most are unaware that they are carriers. Because carriers of cystic fibrosis are unaffected and therefore show no symptoms, it is hard for them to appreciate that cystic fibrosis may be a real risk.

Any one of us could be a carrier and not know it. There are about one million unaware carriers in Australia. In Tasmania, one in 20 people carry the cystic fibrosis gene. This is the second highest rate in the world behind Ireland.

## HOW IS CYSTIC FIBROSIS TREATED?

Management and treatment of cystic fibrosis is lifelong, ongoing and relentless. A person with cystic fibrosis may consume up to 80 capsules daily to help digest food and may require four hours of airway clearance physiotherapy each day. It is important for people with cystic fibrosis to visit a cystic fibrosis treatment centre several times each year so their progress can be monitored.

A person living with cystic fibrosis takes up to one wheelie bin full of medication each year.

Treatment generally involves:

- Intensive daily physiotherapy to clear the lungs
- Enzyme replacement capsules with food to aid digestion
- Antibiotic therapy to treat lung infections
- Aerosol mist inhalations via a nebuliser to help open the airways
- Salt and vitamin supplements
- A nutritious diet that is also high calorie, high salt and high fat
- Daily exercise, which is important to help clear the airways and build core strength.

A person living with cystic fibrosis must do all of this while continuing their normal daily activities like going to school or work.

People with cystic fibrosis are not encouraged to socialise with each other. The risk of cross-infection and exacerbation of lung conditions is too great. That means cystic fibrosis can be a lonely existence because people with cystic fibrosis cannot personally interact to share experiences and offer support.

WHEN AN INFANT RECEIVES THE GENE FROM ONE PARENT, THEY ARE NOT BORN WITH CYSTIC FIBROSIS BUT ARE A LIFELONG SYMPTOMLESS CARRIER, JUST LIKE ONE OF THEIR PARENTS.



DUE TO INFECTION CONTROL ADHERENCE, CYSTIC FIBROSIS IS OFTEN A SOCIALLY ISOLATING DISEASE.

# HOW IS CYSTIC FIBROSIS DIAGNOSED?

Since 1986, all newborns have been subject to a heel prick test. This test is used to screen for a number of conditions, one of which is an indicator for cystic fibrosis. Diagnosis may also result after a baby is born with obvious cystic fibrosis symptoms such as a bowel blockage or failure to “thrive”. The heel prick test does not detect cystic fibrosis in everyone and the sweat test continues to be the definitive test, as high levels of salt in perspiration is extremely common amongst those with cystic fibrosis.



## CARRIER SCREENING

Cystic fibrosis came into the human genome about 5000 years ago and it has survived and spread. Today there is thought to be almost 2000 mutations that lead to cystic fibrosis, some of which are particular to individual families. At the other extreme, one mutation, Delta F508, is present in some 72% of all cases worldwide.

Carriers are symptomless and live normal lives. They are overwhelmingly unaware of their cystic fibrosis carrier status. Yet they have every chance of passing on the gene to the next generation and that generation to the next and so on – it is only a matter of time before a member of the carrier’s family is born with cystic fibrosis.

## WHAT HAPPENS WHEN TWO CARRIERS HAVE CHILDREN?

Two carrier parents have a 25% chance of having a child with cystic fibrosis with each pregnancy.

- 1 in 4 chance the child will have cystic fibrosis
- 1 in 4 chance the child will not have cystic fibrosis (will not have a copy of or be a carrier of the cystic fibrosis gene)
- 2 in 4 chance the child will be a carrier of cystic fibrosis (having one copy of the cystic fibrosis gene)



# 1 NZ OTC SES

OVERVIEW OF  
CYSTIC FIBROSIS  
QUEENSLAND LIMITED

# OUR MISSION

1

Cystic Fibrosis Queensland is the peak community not for profit charity working with and for the increasing number of people living with cystic fibrosis who attend a Queensland Health clinic for treatment.

We advocate for the entire cystic fibrosis community and seek to raise much needed awareness of this debilitating condition - 90% of our income relies on fundraising.

- To be relevant to our community
- To work collaboratively and advocate for our community
- To be effective in the work we do for our community
- To be respectful of our community, our stakeholders and each other.





# LIVES UNAFFECTED

BY CYSTIC FIBROSIS

# OUR VISION

1



WE ALSO SUPPORT LONGER-TERM OBJECTIVES,  
INCLUDING FUNDING RESEARCH.



CYSTIC FIBROSIS QUEENSLAND  
FIRST REGISTERED AS THE  
AUSTRALIAN CYSTIC FIBROSIS  
ASSOCIATION, JULY 1960.

# OUR HISTORY

1

The first meeting took place in the inner-city Brisbane suburb of Annerley. Annual membership was set at one pound and the main task was fundraising appeals; 90% of funds raised were to support research and 10% to provide education to sufferers and their families to manage the chronic illness.



The first Patron was Sir Josiah Francis, Liberal Federal MP who served until his death in 1964. Senator Dame Annabelle Rankin OBE, Liberal Federal MP, was unanimously elected as his replacement due to her advocacy and support for the sector during parliamentary sittings.

In March 1971, Queensland and New South Wales Cystic Fibrosis Associations agreed to work together, with the objective of conducting international liaison, nurturing new state organisations and providing a central body that would promote cystic fibrosis at a national level. It was an important first step on a quest to alleviate the suffering of children afflicted with cystic fibrosis and search for better ways to cope with what was then a largely uncharted disease.

In 1983, the six state and territory organisations formed a national body called Australian Cystic Fibrosis Associations Federation Incorporated. In 1998 it was renamed Cystic Fibrosis Australia

Incorporated. Cystic Fibrosis Australia was established to facilitate and promote the provision of optimal care to all people affected by cystic fibrosis and ensure the best possible quality of life. At the end of April 2003 Cystic Fibrosis Australia became a company Limited by Guarantee.

The national organisation assists the member organisations achieve common objectives in advocacy, funding and collaboration. Cystic Fibrosis Australia develops and manages national clinical improvement programs, consumer engagement initiatives and conducts cystic fibrosis research throughout Australia into the cause, treatments and an eventual cure for cystic fibrosis. The Australian Cystic Fibrosis Research Trust operating within the Cystic Fibrosis Australia corporate structure has supported more than 30 projects valued at more than \$3 000 000.

CYSTIC FIBROSIS QUEENSLAND PROGRAMS ALIGN WITH CLINICAL ADHERENCE TO SUPPORT OUR MEMBERS IN THEIR QUEST TO REDUCE FREQUENCY AND DURATION OF HOSPITALISATIONS.



YOU CAN'T CATCH  
CYSTIC FIBROSIS, YOU  
ARE BORN WITH IT.

# OUR HISTORY



.....

In 1996, work began on developing the Australian Cystic Fibrosis Data Registry and the working model was released in 1998. Cystic Fibrosis Australia is responsible for the funding (through financial contributions from the States and Territories) and data custodianship of the Australian Cystic Fibrosis Data Registry. On 1 September 2016, the Monash Data Registry Centre became the new management company for the Registry. The future of the Australian Cystic Fibrosis Data Registry is in great hands. The move has enabled digital and clinical development to be undertaken.

In 1988, the first International Cystic Fibrosis Conference in the southern hemisphere was held in Sydney and in 1994 Cystic Fibrosis Australia organised the inaugural Australasian Cystic Fibrosis Conference. This allowed the medical, scientific, allied health and lay communities to come together for knowledge gathering, information sharing and understanding of new trends from overseas. The 14th Australasian Cystic Fibrosis Conference will be held in Hobart 2021.


In 2001, under a new constitution, the Cystic Fibrosis Association of Queensland changed its name to Cystic Fibrosis Queensland Limited to better reflect the Federation model. This constitution principally remains in place today.

In 2018, Cystic Fibrosis Queensland started providing support, services and advocacy for cystic fibrosis sufferers living in the Northern Territory, in response to growing numbers. To mark the event, the Northern Territory Administrator, The Honourable Vicki O'Halloran OM accepted our request to be our Northern Territory Cystic Fibrosis Queensland Patron.

His Excellency, the Governor of Queensland the Honourable Paul de Jersey AC, QC, remains the Patron of Cystic Fibrosis Queensland, and together they support the advocacy undertaken by the Chief Executive Officer and the Cystic Fibrosis Queensland Board.

# OUR HISTORY – A TIMELINE

---



**2003**

Cystic Fibrosis Australia became a company Limited by Guarentee.

**2014**

Kalydeco listed on the pharmaceutical benefits scheme for sufferers aged 6 years and under.

**2017**

Kalydeco listed on the pharmaceutical benefits scheme for sufferers aged 2 - 5 years.

**2019**

The Prince Charles Hospital Adult Cystic Fibrosis Centre is renovated to meet infection control standards.

Cystic Fibrosis Queensland Limited to support advocacy for Symdeko to be listed on the pharmaceutical benefits scheme.

Kalydeco listed on the pharmaceutical benefits scheme in August for sufferers aged 12 - 24 months.

Symdeko listed on the pharmaceutical benefits scheme for sufferers aged 12 years and over.

Orkambi listed on the pharmaceutical benefits scheme in August for sufferers aged 2 - 5 years.

**2020**

Cystic Fibrosis Queensland Limited celebrates 60 years of providing education, support, services and advocacy.

Cystic Fibrosis Queensland Limited to support advocacy for Trikafta to be listed on the pharmaceutical benefits scheme.

**2004**

Cystic Fibrosis Queensland opens its' social enterprise bookshop in Nundah.

**2016**

Cystic Fibrosis Queensland Limited relocates to a central location in Toowong.

**2018**

Orkambi listed on the pharmaceutical benefits scheme for sufferers aged 6 years and over.

Cystic Fibrosis Queensland Limited extends its' membership and programs to sufferers in the Northern Territory.

THE SEARCH FOR A CURE CONTINUES AND TOGETHER WE  
CAN ALL LOOK FORWARD TO A FUTURE OF LIVING LIVES  
UNAFFECTED BY CYSTIC FIBROSIS.




CREATING LIVES UNAFFECTED BY CYSTIC  
FIBROSIS - MORE THAN A SEARCH FOR  
A CURE - CYSTIC FIBROSIS QUEENSLAND  
IS ENSURING THAT ALL CYSTIC FIBROSIS  
SUFFERERS LIVE EACH DAY TO THE FULLEST.

# WHERE DO OUR MEMBERS LIVE?

1

QUEENSLAND, NORTHERN NEW SOUTH WALES AND  
NORTHERN TERRITORY



JOIN THE FIGHT TO BREATHE

WE DELIVER PRACTICAL, LIFE  
GIVING PROGRAMS.

A NEBULISER REDUCES TREATMENT  
FROM TWO HOURS TO 20 MINUTES A  
SESSION. THIS TIME SAVING DEVICE ALSO  
IMPROVES ABSORPTION.



# RESPONDING TO THE NEEDS OF OUR MEMBERS



Today, Cystic Fibrosis Queensland raises funds, awareness and advocates for almost 1000 families living with cystic fibrosis. The past 15 years has seen life expectancy for a cystic fibrosis sufferer born today extend from 18 years to just short of 40 years. Cystic fibrosis, once considered a childhood disease, now effects the lives of more adults with the majority of sufferers not living past their twenties.



Ten years ago, Cystic Fibrosis Queensland supported and advocated for approximately 730 cystic fibrosis sufferers and their families. While there is no cure for cystic fibrosis, education and an increased understanding of the disease itself, including the impact of diet, exercise, airway clearance and infection control has extended the lives of many sufferers living with cystic fibrosis. As a consequence, the number of people requiring our help, both today and projected, has increased.

## WORKING ALONGSIDE QUEENSLAND HEALTH

Cystic Fibrosis Queensland works hard to complement Queensland Health programs. Our programs have been created to specifically support clinical adherence – reducing frequency and duration of hospital stays and the financial burden of the disease on our members and on Queensland Health.

## SUBSIDIES FOR NEBULISERS

Cystic Fibrosis Queensland continues to subsidise nebulisers for our members and has introduced the funding of Queensland Health prescribed

airway clearance equipment for our members who are not eligible for the Health Care Card.

## ADVOCACY

The role of Cystic Fibrosis Queensland is to provide support, services and advocate on behalf of cystic fibrosis sufferers and their families. There is no designated State or Federal Government funding for research or treatment of cystic fibrosis.

Cystic fibrosis is a chronic illness and not a disability. Sufferers are not included in the National Disability Insurance Scheme and there is no provision in the Disability Pension. Cystic Fibrosis Queensland focuses on keeping our members well and healthy – reducing both their frequency and duration of hospital stays.

We believe that at a minimum, cystic fibrosis sufferers should be given the same access to government support and services provided to other Queenslanders living with life shortening health conditions. On our members' behalf, we also promote the importance of infection control, especially during periods of hospitalisation.

# A MESSAGE FROM OUR QUEENSLAND PATRON



It is one of the great honours of this governorship to have been Patron since 2014 of Cystic Fibrosis Queensland.

Kaye and I have marked, from our privileged position, real progress and expansion in the organisation during this time: in 2017, the opening of the new headquarters in Toowong; hosting multiple, memorable '65 Roses' events at Fernberg; and visiting, in 2016, the Adult Cystic Fibrosis Ward at The Prince Charles Hospital.

We are very honoured, in 2020, to also be here during Cystic Fibrosis Queensland's historic 60th Diamond Jubilee Anniversary.

At every interaction, we have been astounded, frankly, by the inclusive mission and resolve of the organisation, its supporters and members.

We know of the statistics: one family every four days endures a diagnosis of this disease.

We also know that people with cystic fibrosis are living longer and better, thanks in a major way to Cystic Fibrosis Queensland's defining focus on research, advocacy and practical support for members. The substantial improvements to the Adult Ward at The Prince Charles Hospital during 2019, and the addition of life-saving drugs to the PBS, are but a few examples of the organisation's recent beneficial influence.

I thank and applaud Cystic Fibrosis Queensland for sustaining strong partnerships with Queensland Health, clinicians, researchers and all stakeholders; I know the strength of these relationship- improves the services, advice and support provided to members.

I further thank the Board, management, administrative staff, supporters, members and volunteers, who help move our society closer to the day when we all 'Live unaffected by cystic fibrosis'.

A handwritten signature in black ink that reads "Paul de Jersey".

His Excellency the Honourable Paul de Jersey AC  
Governor of Queensland

QUEENSLAND HAS THE HIGHEST NUMBER OF PEOPLE PER CAPITA LIVING WITH CYSTIC FIBROSIS

1

CYSTIC FIBROSIS QUEENSLAND'S SUCCESS IS UNDERPINNED BY OUR DEDICATED VOLUNTEERS, INTERNSHIP PROGRAM AND BOARD. THESE PEOPLE WORK TIRELESSLY FOR OUR CAUSE AND ARE GENEROUS WITH BOTH THEIR TIME AND SPIRIT.



# OUR NORTHERN TERRITORY PATRON'S MESSAGE



2020 promises to be another exciting year for Cystic Fibrosis Queensland, with many opportunities to build on the great successes of 2019. The last 12 months have been characterised by hard work and passion from all staff, supporters and participants at the organisation, resulting in even more practical support for Australians living with Cystic Fibrosis.

As Northern Territory Patron, I am proud that the Cystic Fibrosis Queensland mission of seeing Lives Unaffected by Cystic Fibrosis is seeing tangible results. All members are now being subsidised with personal nebulisers, which has seen treatment session times reduced from two hours to 20 minutes, and medication more accurately administered and better-absorbed. Yet another great achievement has been the provision of airway clearance equipment and spirometers for rural, regional and remote members, which assists in maintaining wellness between clinical visits. These initiatives are creating truly life-changing outcomes.

I know that this has also been a meaningful year for Cystic Fibrosis Queensland's support of NT Health. The oxygen concentrator donated to Royal Darwin Hospital is a vital piece of equipment for people with reduced lung capacity who are awaiting a lung transplant or at end of life. It is

clear that the work of this organisation continues to make valuable, crucial contributions to the quality of life of countless Territorians.

The annual '65 Roses' morning tea at Government House was an important and enjoyable opportunity to recognise, celebrate and thank Territorians affected by, and working to support those with Cystic Fibrosis. I thank all involved with Cystic Fibrosis Queensland for your continued hard work and achievements, led by CEO, Petrina Fraccaro. As Patron, I very much look forward to continuing to work together over the coming year to increase awareness and support for all Territorians living with Cystic Fibrosis.

I wish you all a successful 2020.

Her Honour the Honourable Vicki O'Halloran AM  
Administrator of the Northern Territory

I VERY MUCH LOOK FORWARD TO CONTINUING MY PATRONAGE IN THE NORTHERN TERRITORY OVER THE COMING YEAR, AND TO WORKING TOGETHER TO INCREASE AWARENESS AND SUPPORT FOR ALL TERRITORIANS LIVING WITH CYSTIC FIBROSIS.



# CHIEF EXECUTIVE OFFICER'S REPORT



Cystic Fibrosis Queensland is the leading peak not-for-profit charity dedicated to providing education, high-quality membership programs, funding for research and advocacy on behalf of the increasing number of people living with cystic fibrosis.

In order to achieve our vision of “lives unaffected by cystic fibrosis” we need to ensure that Cystic Fibrosis Queensland has the resources and capacity to deliver practical support programs and services to the cystic fibrosis community.

Many of these initiatives are included in this Annual Report, and while we can't produce a cure for cystic fibrosis ourselves, we can provide vital support and services that make day-to-day life easier for our members and their families, touched by cystic fibrosis.

Living with a chronic illness is a financial, emotional and physical burden for all involved.

Cystic fibrosis is the most common, life-shortening genetic condition in Australia today. Despite Queensland having per-capita the highest number of people with cystic fibrosis in Australia, not a great deal is known about this chronic illness.

By providing information and raising awareness, we not only relieve parents, carers and families of much of the burden of explaining cystic fibrosis' complexities, but also do more to highlight the urgent need for funding for our programs.

State and Federal Government provide no designated funding for Cystic Fibrosis Queensland's programs. We rely on generous donations from community fundraisers, public and private donors, corporate sponsors and service clubs to meet our financial needs. Cystic Fibrosis Queensland's success is underpinned by our dedicated volunteers, internship program and Board.


These people work tirelessly for our cause and are generous with both their time and spirit.

Ten years ago, when the average life span of a cystic fibrosis sufferer was 18 years, it was considered a childhood disease.

Today, there are more adults living with cystic fibrosis than children. The average life span of a child born today with cystic fibrosis is just short of 40 years. The majority of sufferers do not live beyond their twenties.

.....

CYSTIC FIBROSIS QUEENSLAND SEEKS TO ALLEVIATE THE FINANCIAL, PHYSICAL AND EMOTIONAL BURDEN EXPERIENCED BY PEOPLE LIVING WITH CHRONIC ILLNESS.



NO LONGER A CHILDHOOD DISEASE, THERE ARE MORE ADULTS LIVING WITH CYSTIC FIBROSIS THAN CHILDREN.

# CHIEF EXECUTIVE OFFICER'S REPORT

While there is no cure, we have extended life through better management and improved knowledge of the disease, infection control, diet, exercise and medication, which all play a vital role in the health and wellness of a sufferer. Cystic Fibrosis Queensland advocated on behalf of our adult members for the refurbishment of the cystic fibrosis facilities at The Prince Charles Hospital which opened mid-2019, meeting international standards of care.

As a Federation member, and with a position on the Cystic Fibrosis Australia Board, Cystic Fibrosis Queensland continues to work collaboratively with the Federation, State and Territory members to raise the profile and awareness for our cause Australia-wide.

I am proud to be part of a Federation which has successfully advocated for life changing drugs, like Kayledco, Orkambi and Symdeko to be listed on the pharmaceutical benefits scheme and look forward to working with colleagues to ensure Trikafta is listed in 2020.

The Federation is also delivering a mental wellbeing program to assist members prepare for this increasing change of circumstances in health outcomes.

Together we are working to meet the changing needs of our community.



Petrina Fraccaro

Chief Executive Officer  
Cystic Fibrosis Queensland Limited





CYSTIC FIBROSIS QUEENSLAND WILL CONTINUE TO WORK COLLABORATIVELY WITH CLINICIANS TO COMPLEMENT THE SERVICES PROVIDED BY QUEENSLAND HEALTH AND INCREASE ADHERENCE.

# BOARD CHAIR AND PRESIDENT'S REPORT



On behalf of the Board, I am pleased to introduce the Cystic Fibrosis Queensland 2019 Annual Report. As a former Chief Financial Officer and qualified corporate accountant I have a stake in ensuring that the charity is professionally run and financially viable. I am also a cystic fibrosis grandmother therefore I hold this charity close to my heart.

The Board and staff at Cystic Fibrosis Queensland are committed to our mission – to be relevant to our community, to work collaboratively with stakeholders and to advocate effectively and, most importantly of all, to remain respectful to the community we support. Cystic Fibrosis Queensland has performed well in 2019. Both program delivery and membership have increased and I am particularly proud of the delivery of 148 personal nebulisers to our members in the past two years. This is practical, life-changing equipment which is cost prohibitive to some members.

I would also like to personally congratulate the team on their advocacy effort. With more adults than children living in Queensland with cystic fibrosis, the upgraded 14 bed clinic at The Prince Charles Hospital was much needed and long overdue.

The Board remains focused on strong financial outcomes for Cystic Fibrosis Queensland. All staff have key performance indicators embedded in their position descriptions and regular reviews conducted against their targets. There are no administration staff, reducing overheads and keeping the organisation lean.

Cystic Fibrosis Queensland will continue to work collaboratively with Queensland Health to ensure that we get the best outcomes for our members. On behalf of the Board, I would like to congratulate all Cystic Fibrosis Queensland staff, volunteers and interns for a job well done.

I am proud of Cystic Fibrosis Queensland and the role it plays in ensuring we create today, a better tomorrow, for cystic fibrosis sufferers.

A handwritten signature in black ink, appearing to read 'm. walker'.

Margaret Walker

Board Chair and President  
Cystic Fibrosis Queensland Limited

# ACHIEVEMENTS AGAINST OUR STRATEGIC PLAN: 2017 - 2020



# THE FIVE PILLARS

## COLLABORATION AND ADVOCACY

CF CAN members recruited, trained and participated in media, political meetings and engaged in public speaking.

Collaborated across the Federation to implement the national PBS campaigns at the community level.

NT is now included in our services and support model – ensuring more people with cystic fibrosis receive the support that they need.

We participated in hospital stakeholder meetings and forums – continually seeking to enhance and extend the services provided by government.

## RESEARCH

We annually provide funds for the Australian Cystic Fibrosis Data Registry and this year sponsored a speaker at the 13th Australasian Cystic Fibrosis Conference. Cystic Fibrosis

Research Limited funded an Australian Cystic Fibrosis Research Trust Innovation Grant in 2018 and is looking towards funding further research.

## SERVICE AND FUNDING

People living with cystic fibrosis remain the key beneficiaries of our programs with educational psychosocial programs available for carers and families.

2020 will see the introduction of transition and mental wellbeing programs for all members.

## EDUCATION AND KNOWLEDGE SHARING

QLD Health Clinics and Here to Help You Days remain a critical part of our collaboration and engagement.

CF Smart numbers continue to grow – teachers, educators, parents, carers and all volunteers and staff complete the training when on-boarding.

Our CEO is part of the QLD Health Collaborative which meets quarterly to discuss and review programs and outcomes. Our 2020 Forum and Expo will be held at our social enterprise bookshop, raising profile and awareness for our cause as well as we increase knowledge.

## VISIBILITY - LET'S GET FAMOUS

Our engagement with politicians, stakeholders, government employees and media raises the profile of our cause. Infection control remains at the forefront of our advocacy to be joined by transition and mental well-being in 2020.

This year, as part of our Diamond Jubilee Anniversary, celebratory events and campaigns will continue to raise funds and awareness for our cause.

JOIN OUR FIGHT TO BREATHE AND HELP  
OUR COMMUNITY, BECAUSE THEY ARE  
SICK AND TIRED OF BEING SICK  
AND TIRED



OUR MEMBERS ARE WARRIORS,  
THEY FIGHT TO BREATHE.



breathe

OUR VOLUNTARY BOARD SUPPORT THE  
CEO TO DELIVER ON THE STRATEGIC  
PLAN AND PROVIDE ADVICE IN THEIR  
AREA OF EXPERTISE.

# OUR PEOPLE



## OUR QUEENSLAND PATRON

His Excellency the Honourable Paul de Jersey AC, QC, Governor of Queensland.

## OUR NORTHERN TERRITORY PATRON

Her Honour the Honourable Vicki O'Halloran AM, Administrator of the Northern Territory.

Our voluntary Board support the CEO to deliver on the strategic plan and provide advice in their area of expertise.

Working across the office and our social enterprise bookshop, a small team of 7 (6.4FTE) dedicated staff drive the organisation. Staff are supported by university internships, work for the dole candidates and volunteers to increase capacity. By maintaining low overheads we continue to return a high-percentage of our revenue to our members through our programs.

## CYSTIC FIBROSIS QUEENSLAND BOARD MEMBERS

NAME	POSITION AND APPOINTMENT
Margaret Walker BCom, GAICD	Chair and President 2016
Kim Colyer BBus (Acc), CA	Treasurer 2017
Kirsten Dilena BA (Hons), LB (Hons), GradCert BA	Company Secretary 2017
Ken Freer B. Pharm, MBA, FAIM	Director 2019
Peter Stewart	Director 2016
Connie Arundel LLB	Director 2017
Eamon Dunne BA (Social Work), MA (Health Mgmt) JPQual	Director 2013
Ashleigh Beauchamp BBus (Acct), CA, JPQual	Director 2017
Shane Colquhoun	Director 2018

# CYSTIC FIBROSIS QUEENSLAND MEMBERS

## CYSTIC FIBROSIS QUEENSLAND TEAM MEMBERS

NAME	POSITION
Petrina Fraccaro BA, DipCS, GradCert Bus, GradDip (PR), MBus (IMC), GAICD, PHD candidate	Chief Executive Officer
Vicki Elson-Green B.Bus (DP)	Membership and Services Coordinator
Gemma Nolan CIV TAE, CIII ECEC, CI CS, DipBus (Mkt),	Head of Fundraising
Emily Ledger BA(Hons), CIV LM, DipHRMgt, DipPM	Community Fundraising Coordinator
Sara Benallack BBusMan (Event Man)	Partnerships Coordinator
Rohan Wotherspoon CIII Retail	Bookshop Coordinator
Shannon Nelson BSocSc (Psych)	Bookshop Volunteer Coordinator

## CYSTIC FIBROSIS QUEENSLAND CONSUMER ADVOCACY NETWORK

NAME	POSITION
Petrina Fraccaro	Chief Executive Officer
Rory Morgan	CF Adult Volunteer and Gold Coast Representative
Connie Arundel	CF Adult and Toowoomba Representative Volunteer
Peter Stewart	CF Adult and Sunshine Coast Representative Volunteer
Jodie Sutton	CF Parent and Toowoomba Representative Volunteer
Sonia Marshall	CF Parent and Sunshine Coast Representative Volunteer

## CYSTIC FIBROSIS QUEENSLAND VOLUNTEERS

NAME	POSITION
Margaret Douglas	Office Administration, Events and Fundraising Volunteer
Jim Douglas	Events and Fundraising Volunteer
Isaac Webster	Office Administration
Lester Yap	Office Administration
Grace Harmer	Events and Fundraising Volunteer
Martin Bevis	Events and Fundraising Volunteer
Sarah Matthews	Events and Fundraising Volunteer
PuiKa (Joey) Ho	Events and Fundraising Volunteer
Shannon O'Brien	Events and Fundraising Volunteer
Hoi Ying (Sarah)	Events and Fundraising Volunteer
Cheung	Events and Fundraising Volunteer
Jincy (Jin) Jose	Events and Fundraising Volunteer
Laynee Tan	Events and Fundraising Volunteer
Lindsay Killeen	Events and Fundraising Volunteer
Ana Maria Fuentes Diaz	Events and Fundraising Volunteer
Amy Anderson	Events and Fundraising Volunteer

## CYSTIC FIBROSIS QUEENSLAND BOOKSHOP VOLUNTEERS

<b>NAME</b>	<b>POSITION</b>
Adam Webber	Bookshop Volunteer
Anne Brehmer	Bookshop Volunteer
Anne Ross	Bookshop Volunteer
Brett Johnson	Bookshop Volunteer
Carmen Sempf	Bookshop Volunteer
Chris Klease	Bookshop Volunteer
Daniel Barker	Bookshop Volunteer
Daniel Gardiner	Bookshop Volunteer
Deb Kong	Bookshop Volunteer
Elske Shaw	Bookshop Volunteer
Gabrielle Lee	Bookshop Volunteer
Genevieve Lee	Bookshop Volunteer
Grace Cassidy	Bookshop Volunteer
Jack Palmer	Bookshop Volunteer
Jake Gould	Bookshop Volunteer
Jeff Suttle	Bookshop Volunteer
Jenny Egerton	Bookshop Volunteer
Jillian Keane	Bookshop Volunteer
Joel Perry	Bookshop Volunteer
John Scott	Bookshop Volunteer
Karen Clark	Bookshop Volunteer
Kathryn White	Bookshop Volunteer



NAME	POSITION
Lachlan McDonald	Bookshop Volunteer
Lisa Walker	Bookshop Volunteer
Louen Wright	Bookshop Volunteer
Pam Dent	Bookshop Volunteer
Patricia Lowrie	Bookshop Volunteer
Paul Barnes	Bookshop Volunteer
Peter Ridgway	Bookshop Volunteer
Roslyn Eyles	Bookshop Volunteer
Sarah Hundal	Bookshop Volunteer
Sarah Taylor	Bookshop Volunteer
Shane Jones	Bookshop Volunteer
Shirley Higgins	Bookshop Volunteer
Stephanie Burgess	Bookshop Volunteer
Susan Dixon	Bookshop Volunteer
Tamlin Hall	Bookshop Volunteer
Vikki Payne	Bookshop Volunteer



## CYSTIC FIBROSIS QUEENSLAND INTERNSHIPS


<b>NAME</b>	<b>UNIVERSITY</b>
Tian (Lyndon) Lu	Queensland University of Technology
Yu (Ivy) Ma	Queensland University of Technology
Rushali Fernandez	University of Queensland

## CYSTIC FIBROSIS QUEENSLAND BOOKSHOP VOLUNTEER CHOIR

<b>NAME</b>	<b>POSITION</b>
Tina Shaw	Choir Mistress Volunteer
Sarah Hundal	Choir Member Volunteer
Karen Long	Choir Member Volunteer
Jessica MacDonald	Choir Member Volunteer

# STRUCTURE AND MANAGEMENT

Cystic Fibrosis Queensland Limited registered with the Australian Charities and Not-for-profits Commission (ACNC). All Cystic Fibrosis Queensland Directors contribute on a voluntary basis.



# SECTION 2

HOW WE ARE MAKING  
A DIFFERENCE

IN AUSTRALIA,  
EVERY FOUR DAYS A  
CHILD IS BORN WITH  
CYSTIC FIBROSIS.

**There is no cure for cystic fibrosis. The increase in the number of people requiring our help is the highest it has ever been and continued growth is expected. Thanks to better knowledge and improved understanding about the disease, cystic fibrosis people are living longer today than ever before.**

We are no longer a charity providing care just for children. More than 52% of people with cystic fibrosis in Australia are adults and we need to continue evolving to provide support and services that reflect their needs.

Our community and clinicians helps us to shape the support and services we provide through our annual membership survey.

## 65 ROSES PATRONS' MORNING TEA

A highlight in the 65 Roses Month of May calendar is when our Patron, The Governor of Queensland, His Excellency the Honourable Paul de Jersey AC QC and Mrs Kay de Jersey open their home to our Cystic Fibrosis Queensland members, staff, board, volunteers and supporters. This event provided an opportunity for all sectors of our community to come together, celebrate achievements and recognise our commitment to our goal – to live lives unaffected by cystic fibrosis.

Our Northern Territory Patron, The Administrator of the Northern Territory, The Honourable Vicki O'Halloran AM also opened her home to our community and clinicians based in Darwin. It is important to ensure that our programs continue to meet the needs of cystic fibrosis sufferers living in rural, regional and remote areas.

## 2019 CLIENT SURVEY

Cystic Fibrosis Queensland's 2019 survey received 149 responses. Cystic Fibrosis Queensland can be certain that the 2019 survey confidence level is 90% with a 5% margin of error. The results from this annual survey continue to shape the programs delivered by Cystic Fibrosis Queensland. Anxiety about the future remains a priority for all members. The high prevalence of mental health concerns among the cystic fibrosis community was addressed through the Mental Health Road show- jointly delivered by Cystic Fibrosis Australia and the Cystic Fibrosis Federation and funded by LJHooker. Advocacy and funding research also remains a priority for members.

CYSTIC FIBROSIS QUEENSLAND SEEKS TO ALLEVIATE THE FINANCIAL, PHYSICAL AND EMOTIONAL BURDEN EXPERIENCED BY PEOPLE LIVING WITH CHRONIC ILLNESS.

OUR PRACTICAL PROGRAMS SHOULDER THE  
BURDEN OF CHRONIC ILLNESS.



CYSTIC FIBROSIS QUEENSLAND  
STRIVES TO COMPLEMENT THE  
CARE AND TREATMENT PROVIDED  
BY QUEENSLAND HEALTH.

# OUR PROGRAMS

# 2

.....

**Our programs range from emergency relief to tangible life-giving equipment. By working with Queensland Health we have been able to construct a scaffold that supports our members' clinical adherence. While we wait for a cure, we continue to focus on member wellness in a bid to reduce frequency and duration of hospital stay.**

## HOSPITAL PARKING, TAXI AND RIDE SHARE VOUCHERS

This subsidy was introduced in 2017 and remains popular. It supplements the current government subsidy to relieve some of the out-of-pocket expenses associated with frequent hospitalisation.

## EDUCATION

Cystic Fibrosis Queensland educates the broader community about the disease, raising awareness of the chronic illness for advocacy and funding purposes. This also alleviates the need for people with cystic fibrosis, and their families to provide explanation.

## CF SMART

This free online educational resource provides information for educators, teachers, parents, students and health professionals. The training contributes to recognised professional development points. Our team is also available to meet with schools and discuss the learning covered by CF Smart.

## CYSTIC FIBROSIS QUEENSLAND FORUM AND EXPO

This annual event provides an opportunity for clinicians, community workers, support services and equipment manufacturers to speak with our members directly through presentations followed by an expo.

## HERE TO HELP YOU DAYS AND CLINICS

Our Services people participate in the quarterly open days at the Queensland Children's Hospital and attend clinics monthly. This is an informal way for families to meet with the team to ask questions about our charity and our programs.

## CHILDREN'S HEALTH QUEENSLAND COMMUNITY COLLABORATIVE

Our CEO participates in this quarterly forum which includes senior hospital staff as well as leaders from other charities which support the work of the hospital. This is a robust forum focused on education and collaborative opportunities. One such outcome has been the opportunity to jointly fund capital expenditure requests made by cystic fibrosis clinicians.

## LITTLE DAY OUT

This new psychosocial activity was launched late 2018. This inclusive program was taken up by cystic fibrosis adults who have children as well as families whose children have cystic fibrosis. This subsidy allowed for families to take a day off from thinking about and dealing with the complications of cystic fibrosis and enjoy a day out in a family activity of their choice.

THE SEARCH FOR A CURE CONTINUES AND TOGETHER  
WE CAN ALL LOOK FORWARD TO A FUTURE OF LIVING  
LIVES UNAFFECTED BY CYSTIC FIBROSIS.

## LOAN EQUIPMENT

When cystic fibrosis sufferers' personal nebulisers are in for repair, or unsuitable to travel with, our members draw on our stock of loan equipment. This is an often called on service for our members and highlights the need to maintain stock in good working order and continually upgrade when finances allow. Due to the cost of personal compressors and nebulisers, some members rely on loan equipment from Cystic Fibrosis Queensland, delaying the purchase of new and/or upgraded models.

## NEBULISERS

Applications for the subsidy to purchase this equipment for use either in the home or for travel is gathering momentum, as families and individuals look to purchase their first or to upgrade their nebuliser.

## AIRWAY CLEARANCE DEVICES

Cystic Fibrosis Queensland supplements the supply of Queensland Health physiotherapist prescribed airway clearance devices available to the community.

## GYM EQUIPMENT

Recovery time during hospital stays is supported by the provision of equipment for hospital gyms.

Modern exercise equipment including stationery exercise bikes, treadmills, and weights have previously been provided to Queensland Health by Cystic Fibrosis Queensland to improve the range of rehabilitative exercises physiotherapists can prescribe to patients. As some of this equipment is easily maneuvered into hospital rooms, isolated patients can stay active within the hygienic confines of their individual rooms.

## TRAMPOLINES

Exercise in disguise! Some children don't enjoy exercise and others struggle to adhere to an exercise schedule. A trampoline is a fun exercise tool and provides excellent respiratory clearance. This subsidy was introduced early 2018 and is proving to be incredibly popular with our cystic fibrosis families.

## PHYSICAL ACTIVITY SUBSIDIES

In previous years, physical activity subsidies (PAS) have only been available to cystic fibrosis sufferers when provided by a grant. Daily physical activity is important for airway clearance and helping the immune system remain strong to fight off exacerbations. All members are eligible for an annual PAS claim to spend on exercise of their choice.

## BOREDOM BUSTER BAGS

Filled with age and gender appropriate items, these bags help cystic fibrosis children pass time and alleviate the boredom of treatment and hospital stays. Information about available support and services is also included in the bags which are delivered weekly.

# OUR PROGRAMS

# 2

## Supporting Queensland and Northern Territory Departments of Health with exercise and medical equipment



**The Prince Charles Hospital  
Adult Cystic Fibrosis Centre**

### 2018

- Aerobika x 5
- Acapella x 1
- AeroEclipse x1
- Pari PEP S x 3
- Recumbent bike

### 2019

- Aerobika x 6
- LC Sprint
- Pari PEP S x 4
- Pari PEP System x 1
- Eclipse SeQual 5  
- oxygen concentrator
- My Airvo home humidifier
- Innospire Go x 3



**The Mater Young Adults Health  
Clinic - Cystic Fibrosis Centre**

### 2018

- Aerobika x 1 • Spin Bike
- Cross Trainer • Dumbbells
- Aerobic Step • Futsal balls
- Volleyball • Mini trampoline
- Skipping ropes • Boxing gloves
- Foam roller • Reebok mat
- Weight bag • EllipticalTreadmill
- Fridges x 2

### 2019

- Acapella x 1
- Pari PEP System x 1



**Queensland Children's Hospital  
- Cystic Fibrosis Ward**

### 2018

- ERapid Aerosol
- Head x 2
- Aerobika x 3
- Pari LC Sprint x 4
- Pari PEP S x 6
- Pari PEP System x 1
- Fridges x 48

### 2019

- Aerobika x 4
- AeroEclipse x 1
- Pari LC Sprint x 5
- Pari PEP System x 1
- Pari PEP S x 6
- TheraPEP x 2

### 2019

- Strengthening Cystic Fibrosis Physiotherapy Across Queensland - supported professional development for 11 physiotherapists
- CF Paediatric Management - supported professional development for 7 nurses
- Provided subsidies to 8 clinicians to attend the 13th Australasian Cystic Fibrosis Conference



**Royal Darwin Hospital**

### 2019

- Philips Simply Go Mini x 1

50% OF PEOPLE BORN WITH CYSTIC FIBROSIS  
WILL NOT SURVIVE PAST THEIR TWENTIES.



PEOPLE DIAGNOSED WITH CYSTIC  
FIBROSIS FACE A DAILY REGIME OF  
MEDICATION AND PHYSIOTHERAPY -  
JUST TO BREATHE.

# OUR IMPACT

# 2

Our annual membership survey informs our programs. Next year will see an increase to our parking subsidy and the introduction of a new subsidy to support the on-going costs of medication.

## HOW DID WE GO?

### PHYSICAL ACTIVITY TOTAL 371



### PARKING TOTAL 231



### TRAMPOLINES TOTAL 100



### AIRWAY CLEARANCE TOTAL 60



### NEBULISERS TOTAL 148



### BOREBOM BUSTER BAGS TOTAL 447



### IN HOSPITAL VOUCHERS TOTAL 67



### LITTLE DAY OUT TOTAL 160



### L.K.I. BAGS TOTAL 160



### CF SMART TOTAL 297



### PERSONAL FANS TOTAL 50



## ADVOCATING FOR OUR MEMBERS



### Hospital prescribed physiotherapy equipment

Queensland Health provide to our members holding health care cards. For non-card holders, Cystic Fibrosis Queensland provides this equipment



### Refurbished facilities for adults

14-bed clinic at The Prince Charles Hospital Adult Cystic Fibrosis Centre opened mid 2019

## ACKNOWLEDGING OUR MEMBERS, SUPPORTERS AND VOLUNTEERS



65 Roses Patrons Event Queensland. Morning Tea hosted by Queensland Governor



65 Roses Patrons Event Northern Territory. Morning Tea hosted by Northern Territory Administrator

## ALLEVIATING THE FINANCIAL BURDEN



Cleaning subsidies, clearing dust and mould from the home



Provision of personal fans



Hospital Parking Subsidies

## EDUCATING OUR COMMUNITY



CFSmart recognised professional development for educators, carers, parents and volunteers



School visits



Queensland Children's Hospital Here to Help you Day



Queensland Children's Hospital Clinic Visits



Children's Health Queensland Community Collaborations

# CREATING A FUTURE

# 2

## SUPPORTING RESEARCH

### AUSTRALIAN CYSTIC FIBROSIS RESEARCH TRUST

The Australian Cystic Fibrosis Research Trust continues to fund Australian cystic fibrosis researchers and in recent years, the following topics have been explored: gene therapy, cystic fibrosis transmembrane conductance regulator modulators, mental health, organoids, rare mutations, biofilms, antimicrobial resistance, macrophages, exercise and cystic fibrosis, the microbiome and gastro issues plus multiple breath washouts and CT scans.

### AUSTRALIAN CYSTIC FIBROSIS RESEARCH TRUST

Innovation Grants, valued at \$80,000 annually, and designed to support post doctoral researchers to explore novel concepts at the initial feasibility stage. Funding for Innovation Grant

Top Up Scholarships, three per year of \$5,000 each, for post-graduate students to attract the brightest young minds to cystic fibrosis research.

Special Interest Grants, ranging from \$10,000 to \$100,000 annually, support specific research communities or research areas. The Ann Maree Bosch Fellowship for early career scientists to facilitate cystic fibrosis researchers learning new techniques and establishing research collaborations and the David Millar Giles Grant focusing on rare mutations are just two examples.

As the cystic fibrosis survival rates improve and the community grows the Australian Cystic Fibrosis Research Trust's commitment to funding cystic fibrosis research that will reduce the burden of the disease, becomes more steadfast.

### CYSTIC FIBROSIS RESEARCH LIMITED

Cystic Fibrosis Research Limited is dedicated to funding research into the treatment and eventual cure of cystic fibrosis. Cystic Fibrosis Queensland has representation on the Board of Cystic Fibrosis Research Limited. In the 2018/2019 year, the Trust fully funded a \$70 000 Australian Cystic Fibrosis Research Trust Innovation Grant into ribonucleic acid (RNA) therapeutics treatments. RNA therapy modifies or provides ribonucleic acid to patients' cells. The research looked at whether RNA based therapeutic treatments for other disorders can establish drug delivery techniques that will effectively translate BGas (gene manipulation) suppressing compounds into an innovative cystic fibrosis therapy. Cystic Fibrosis Research Limited anticipates that it will be providing further funding to new research projects in 2020.

**Cystic Fibrosis Queensland works collaboratively with both trusts to ensure funding is provided to leading cystic fibrosis research projects which will be of the greatest benefit to the majority of Australians living with cystic fibrosis.**

# SECTIONS

## ACCOUNTABILITY

# DIRECTOR'S REPORT

# 3

**The directors present this report on Cystic Fibrosis Queensland Ltd for the financial year ended 31 December 2019.**

## DIRECTORS

**The names of each person who has been a director during the year and to the date of this report are:**

Margaret Walker (Chair)  
Kim Colyer (Treasurer)  
Kirsten Dilena (Company Secretary)  
Eamon Dunne  
Peter Stewart  
Ashleigh Beauchamp  
Connie Arundel  
Shane Colquhoun  
Ken Freer (appointed 10 July 2019)  
Lisa Nixon (resigned 13 April 2019)

**Directors have been in office since the start of the financial year to the date of this report, unless otherwise stated.**

## PRINCIPAL ACTIVITIES

The principal activity of the company during the financial year was to provide emotional support to children, adults and their families through counselling and respite programs, practical support through equipment (for those without a health care card), physiotherapy, accommodation and special support for children during hospital stays, public advocacy, and education programs to the community.

## SHORT-TERM AND LONG-TERM OBJECTIVES

The company's short-term objectives are to:

- Support those people in Queensland and other jurisdictions who are required to access Queensland hospitals due to cystic fibrosis (CF) with the goal to live a life not affected by CF;
- Support families to meet the needs of a CF person in their lives;
- Support community agencies such as childcare centres, schools, workplaces and

community physiotherapists to understand the requirements of a person with CF; and

- Develop fundraising programs to enable the company to meet these goals.

The company's long-term objectives are to:

- Communicate to current and future clients via a range of mediums to reach people who live throughout Queensland, Northern New South Wales, the Northern Territory and Tasmania;
- Remain updated with any new developments and directions relating to the management of CF; and
- Remain sustainable through fundraising efforts and continue to lobby government for a more equitable ongoing grant.

## STRATEGIES

To achieve its state objectives, the company has adopted the following strategies:

- Review operations to drive cost efficiencies, reduce historical debt and consider ongoing sustainability.
- Ensure that staff employed by Cystic Fibrosis Queensland Ltd (CFQ) are appropriately skilled as well as aligned with CFQ's vision of 'lives unaffected by Cystic Fibrosis'
- To be relevant and to add value to the CF community as a point of first contact for information about CF in Queensland; and
- To engage in activities that create a better awareness of CF in the community and become better aligned with the national body to affect campaigns that implement real change for the

## KEY PERFORMANCE MEASURES

The company measures its own performance through the use of both quantitative and qualitative benchmarks. The benchmarks are used by directors to assess the financial sustainability of the company and whether the company's short-term and long-term objectives are being achieved.

# DIRECTOR'S REPORT

---

## OUR DIRECTORS

### MARGARET WALKER | CONTINUING

#### Chair

**Qualifications** | B Com, GAICD

Margaret Walker is President and Chair of Cystic Fibrosis Queensland Limited. She is also a member of the Audit Committee for the Australian Institute of Marine Science in Townville and Suburban Land Agency in Canberra. Margaret's previous board positions include Defence Housing Australia, Buderim Ginger, Tactical Global Management and Cystic Fibrosis Australia.

With a strong and extensive background in senior finance executive roles, Margaret brings to any board strong financial, regulatory and risk management experience as well as an informed, practical approach to corporate strategy and program monitoring. Margaret is also a Director of Cystic Fibrosis Research Limited and the Australian Cystic Fibrosis Research Trust.

### EAMON DUNNE | CONTINUING

#### Director

**Qualifications** | BA (Social Work), MA (Health Management), JP (Qual)

Eamon has an extensive background in health management and social work. He is well versed in Healthcare Management, Performance Improvement and Project Management. Eamon is the current Community Health Assistant Director and Senior Manager - Sunshine Coast Hospital and Health Service.

### PETER STEWART | CONTINUING

#### Director

Peter is a Resource Planning Manager at Virgin Australia. He brings to the board experience in a workforce and capacity operations, planning, strategy and forecasting. As our adult Cystic Fibrosis Queensland Limited Board member, Peter is a critical link in building and maintaining the relationship between our client members and strategic objective of the board. Peter is also a member of the Cystic Fibrosis Consumer Advocacy Network and sits on the Cystic Fibrosis Advisory Committee, The Prince Charles Hospital.

### KIM COLYER | CONTINUING

#### Treasurer

**Qualifications** | BBus (Acc) CA

Kim Colyer has over 20 years' audit experience and has been a partner at BDO since 2007. As Treasurer, she brings in-depth knowledge and experience of general purpose reporting, corporations law and other disclosure requirements to Cystic Fibrosis Queensland Limited. This extensive experience has assisted Kim while working with clients across multiple industries and sectors, particularly Not-For-Profit organisations.

### ASHLEIGH BEAUCHAMP | CONTINUING

#### Director

**Qualifications** | BBus (Accounting), CA, JP (Qual)

Ashleigh Beauchamp has over 7 years' business services experience and has been at BDO since 2012. She brings knowledge and experience of financial reporting, accounting and taxation to Cystic Fibrosis Queensland Limited.

### CONNIE ARUNDEL | CONTINUING

#### Director

**Qualifications** | LLB

Connie Arundel is a Solicitor in Commercial/Property Law and Wills and Estates at Shine Lawyers. Connie has cystic fibrosis and has received a double lung transplant. Connie will bring both youth and experience to the Board as a recipient of medical services over her lifetime. She has a particular interest in ensuring that basic standards are met in health care and has empathy for people who live with the disease.

### KIRSTEN DILENA | CONTINUING

#### Company Secretary

**Qualifications** | BA (Hons); Graduate Certificate in Business Administration

Kirsten brings to the board over 16 years in commercial and legal roles specialising in commercial and corporate law, procurement and corporate transactions, governance and compliance and regulatory advice. Kirsten has a background of briefing, advising and sitting on Boards and committees in the government and not-for-profit sectors and brings a combination of commercial and legal governance as well.



### SHANE COLQUHOUN | CONTINUING

#### Director

Approaching 20 years in the real estate industry, Shane is the Business owner at LJ Hooker Nerang and current President of the LJ Hooker Franchise Owners Council, serving within the elected group since 2012.

Shane is proud to boast numerous industry awards from his “real estate family” including more recently the coveted 2018 Franchise Owner of the Year.

Shane’s group of offices have been proud supporters of the Cystic Fibrosis community since 2003 when introduced to CF through the LJ Hooker ‘Partnership in Caring’ arrangement which was established in 1998. LJ Hooker Corporate and its network of offices have contributed well over \$5 million to help people with Cystic Fibrosis and their families.

### KEN FREER | CONTINUING

#### Director - appointed July 2019

**Qualifications** | B Pharm, MBA (Insead), FAIM

Ken has over 25 years experience in fast moving consumer goods with senior roles in general management, sales and marketing having worked for Wellcome Australia, Reckitt & Colman, PepsiCo Foods International (Frito-Lay) and Lion Nathan as Managing Director of Castlemaine Perkins.

Currently he is Senior Associate with BlueMount Capital and an advisory board director of Transport for Brisbane. Previous board roles include director of Moreton Bay College and Moreton Bay Boys College, Chairman of Dealer Trade Holdings and Director of the Playground &

Recreation Association of Queensland. Ken has previously held roles as General Manager for the Lexmark Indy 300, Director of Motorsport for IMG and the CEO for Queensland Rugby and the Reds.

### LISA NIXON | RESIGNED 13 APRIL 2019

#### Director

**Qualifications** | BA (Journalism), MPRIA, RIMER Cert. CM

Lisa is a highly experienced communications strategist and team leader with more than 25 years’ experience. Lisa’s strength lies in complex problem solving and issues management.

Lisa has worked at length with public and private sector organisations on campaigns to inform, engage or persuade audiences on a range of matters including healthcare reforms and products, contentious property development issues, new business and product launches and Australian market entry strategies. She has led communications for organisations undergoing change, including mergers, acquisitions, redundancy and insolvency. Her value to clients comes in her ability to comprehend the larger businesses issues and to focus the communications strategic approach to that bigger picture. Lisa is currently a Managing Director with BBS. Lisa also sits on the Board of Cystic Fibrosis Research Limited. and experience of general purpose reporting, corporations law and other disclosure requirements to Cystic Fibrosis Queensland Limited. This extensive experience has assisted Kim while working with clients across multiple industries and sectors, particularly Not-For-Profit organisations.



THE PERSONAL NEBULISER SUBSIDY, TO USE EQUIPMENT EITHER IN THE HOME OR FOR TRAVEL, IS GATHERING MOMENTUM.

## MEETING OF DIRECTORS

During the financial year, seven meetings of directors were held. Attendances by each director were as follows:

### DIRECTORS' MEETINGS

NAME	NUMBER ELIGIBLE TO ATTEND	NUMBER ATTENDED
Margaret Walker (Chair)	7	7
Eamon Dunne	7	6
Peter Stewart	7	6
Lisa Nixon	1	1
Kim Colyer	7	6
Ashleigh Beauchamp	7	6
Connie Arundel	7	6
Kirsten Dilena (Company Secretary)	7	7
Shane Colquhoun	7	6
Ken Freer	4	3

The company is incorporated under the Corporations Act 2009, but now governed by the Australian Charities and Not-for-Profits Commission Act 2002 and is a company limited by guarantee. If the company is wound up, the constitution states that each Director is required to contribute a maximum of \$1 each towards meeting any outstanding obligations of the company. At 31 December 2019, the total amount that Directors of the company are liable to contribute if the company is wound up is \$9.

### AUDITOR'S INDEPENDENCE DECLARATION

The lead auditor's independence declaration for the year ending 31 December 2019 has been received and can be found on page 7 of the financial report.

The directors' report is signed in accordance with a resolution of the Board of Directors.



M Walker  
Director  
20/03/19



K. L. Colyer  
Director  
20/03/19

# TREASURER'S REPORT



I am pleased to present the audited financial statements of Cystic Fibrosis Queensland for the year ended 31 December 2019. The financial result for Cystic Fibrosis Queensland ended in a deficit for the year of \$287,662 (compared to prior year \$97,193). The main contributors to the decline in the result is a reduction of grant income of \$23,399, fundraising income from corporate events of \$84,071 and a loss on the sale of Rose Cottage of \$147,031.

The loss on the sale of Rose Cottage has been recognised as result of the asset previously booked at fair value and therefore fair value movements were previously recognised in an asset revaluation reserve. The sale of Rose Cottage for \$430,000, resulted in an amount that was previously booked in the asset revaluation reserve of \$302,941 being transferred to retained profits. As a result of the Rose Cottage sale and improved management of our operating costs, we have a surplus working capital position, and have been able to pay long overdue creditors (including our national levy), our GST liability of \$21,813 that was owing to the ATO and at reporting date our cash balance is at \$194,035.

Our bookshop income has increased from \$187,961 to \$204,570 and our corporate events income has declined. Due to the fixed costs required to deliver corporate events and the amount of effort

and resources to coordinate, and that there is also no guarantee we are able to breakeven, it was decided that our efforts were better focused on smaller and more frequent community fundraising campaigns. This has proven to be a prudent decision.

Included in our balance sheet is a new asset called Right-of-use assets and the corresponding Lease liability. These balances have been booked this year as a result of adopting the new accounting standard AASB16 Leases. Under AASB16, we no longer disclose a rental expense, however the cost of the lease is now disclosed as a combination of interest expense and amortisation expense. The lease accounting balances represent our future operating lease costs in relation to the Cystic Fibrosis Queensland office at Toowong and the bookshop at Nundah.

Thank you to Petrina our CEO for managing our costs and to HLB Mann Judd for their accounting and audit assistance throughout the period.

A handwritten signature in black ink, appearing to read 'Kim Colyer'.

Kim Colyer

Treasurer  
Cystic Fibrosis Queensland



REMAIN SUSTAINABLE THROUGH  
FUNDRAISING EFFORTS  
AND CONTINUE TO LOBBY  
GOVERNMENT FOR A MORE  
EQUITABLE ONGOING GRANT.

# AUDITOR'S INDEPENDENCE DECLARATION



## AUDITOR'S INDEPENDENCE DECLARATION

We declare that, to the best of our knowledge and belief, there have been no contraventions of any applicable code of professional conduct in relation to the audit of the financial report of Cystic Fibrosis Queensland Ltd for the year ended 31 December 2019.

A handwritten signature in black ink that reads 'HLB Mann Judd'.

HLB Mann Judd  
Chartered Accountants  
Brisbane, Queensland 15 March 2018

A handwritten signature in black ink that reads 'A B Narayanan'.

A B Narayanan  
Partner

[hlb.com.au](http://hlb.com.au)

**HLB Mann Judd (SE Qld Partnership)**

Level 15, 66 Eagle Street, Brisbane QLD 4000 | GPO Box 5225 Brisbane QLD 4001

**T:** +61 (0)7 3001 8800 **F:** +61 (0)7 3221 0812 **E:** [infobne@hlbqld.com.au](mailto:infobne@hlbqld.com.au)

Liability limited by a scheme approved under Professional Standards Legislation.

HLB Mann Judd (SE QLD Partnership) is a member of HLB International, the global advisory and accounting network.

COMMUNICATE TO CURRENT AND FUTURE CLIENTS VIA A RANGE OF MEDIUMS TO REACH PEOPLE WHO LIVE THROUGHOUT QUEENSLAND, NORTHERN NEW SOUTH WALES AND THE NORTHERN TERRITORY.



# FINANCIAL POSITION

	NOTE	\$ 2019	\$ 2018
<b>ASSETS</b>			
Current Assets			
Cash and cash equivalents	5	194,035	450
Trade and other receivables	6	5,720	18,176
Inventories	7	-	6,010
Other assets	8	13,102	6,016
Total Current Assets		212,857	30,652
Non-Current Assets			
Trade and other receivables	6	8,800	8,800
Property, plant and equipment	9	-	593,112
Right-of-use assets	10	474,522	
Total Non-Current Assets		483,322	601,912
TOTAL ASSETS		696,179	632,564
<b>LIABILITIES</b>			
Current Liabilities			
Trade and other payables	11	46,561	144,154
Financial liabilities	12	2,003	6,668
Lease Liabilities	13	66,624	-
Employee benefits	14	20,523	30,686
Income received in advance	15	20,807	46,526
Total Current Liabilities		156,518	228,034
Non-Current Liabilities			
Lease Liabilities	13	422,793	-
Total Non-Current Liabilities		422,793	
TOTAL LIABILITIES		579,311	228,034
NET ASSETS		116,868	404,530
<b>EQUITY</b>			
Retained Surplus		116,868	101,589
Asset Revaluation Reserves	18		302,941
TOTAL EQUITY		116,868	404,530

# STATEMENT OF PROFIT OR LOSS AND OTHER

# 3

NAME	NOTE	\$ 2019	\$ 2018
Revenue	3	1,467,875	1,684,772
Employee benefits expense		(889,694)	(990,096)
Depreciation and amortisation		(80,317)	(16,434)
Events		(107,751)	(182,271)
Finance costs		(23,862)	(17,582)
Fundraising and marketing		(108,512)	(154,626)
Loss on sale of property, plant and equipment		(147,031)	-
Occupational expenses		(32,468)	(71,811)
Other operating expenses		(186,281)	(195,644)
Support services		(179,621)	(153,501)
Surplus/(deficit) before income tax		(287,662)	(97,193)
Income tax expense			
Surplus/(deficit) from continuing operations	4	(287,662)	(97,193)
Surplus/(deficit) for the year			(97,193)
Items that will not be reclassified subsequently to profit or loss			
Gain on revaluation of land and buildings			163,346
Other comprehensive income for the year, net of tax			163,346
Total comprehensive income for the year		(287,662)	66,153

# STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED 31 DECEMBER 2019

## 2018

	Retained Surplus \$	Asset Revaluation Reserve \$	Total \$
Balance at 1 January 2018	198,782	139,595	338,377
Surplus/(deficit)	(97,193)	-	(97,193)
Other comprehensive income	-	163,346	163,346
Balance at 31 December 2018	101,589	302,941	404,530

## 2019

	Retained Surplus \$	Asset Revaluation Reserve \$	Total \$
Balance at 1 January 2019	101,589	302,941	404,530
Surplus/(deficit)	(287,662)	-	(287,662)
Other comprehensive income for the year	-	-	-
Transfer to retained earnings on disposal of property, plant & equipment	302,941	(302,941)	-
Balance at 31 December 2019	116,868	-	116,868

OUR PROGRAMS CONTINUALLY EVOLVE TO REFLECT CYSTIC FIBROSIS QUEENSLAND MEMBERS NEEDS.

# STATEMENT OF CASH FLOWS

# 3

FOR THE YEAR ENDED 31 DECEMBER 2019

	NOTE	\$ 2019	\$ 2018
<b>CASH FLOW FROM OPERATING ACTIVITIES</b>			
Receipts from customers		1,076,080	1,126,211
Payments to suppliers and employees		(1,251,146)	(1,190,924)
Interest received		16,519	115
Interest Paid		(23,862)	(1,509)
Net cash provided by (used in) operating activities		(182,409)	(66,107)
<b>CASH FLOW FROM INVESTING ACTIVITIES</b>			
Proceeds from disposal of Property, plant and equipment		429,469	-
Net cash used by investing activities		429,469	-
<b>CASH FLOW FROM FINANCING ACTIVITIES</b>			
Proceeds (repayment) of borrowings		(4,665)	4,700
Repayment of Lease liabilities		(48,810)	-
Net cash used by financing activities		(53,475)	4,700
Net increase (decrease) in cash and cash equivalents held		193,585	(61,407)
Cash and cash equivalents at beginning of year		450	61,857
Cash and cash equivalents at end of financial year	5	194,035	450

# NOTES TO THE FINANCIAL STATEMENTS

---

FOR THE YEAR ENDED 31 DECEMBER 2019

The financial statements cover Cystic Fibrosis Queensland Ltd as an individual company, incorporated and domiciled in Australia. Cystic Fibrosis Queensland Ltd is a company limited by guarantee.

## 1. Summary of Significant Accounting Policies

### (a) Basis of Preparation

These general purpose financial statements have been prepared in accordance with the Corporations Act 2001 and Australian Accounting Standards – Reduced Disclosure Requirements of the Australian Accounting Standards Board and the Australian Charities and Not-for-Profits Commissions Act 2012. The company is a not-for-profit company for financial reporting purposes under Australian Accounting Standards. Material accounting policies adopted in the preparation of these financial statements are presented below and have been consistently applied unless otherwise stated.

The financial statements, except for the cash flow information, have been prepared on an accrual basis and are based on historical costs, modified, where applicable, by the measurement at fair value of selected non-current assets, financial assets and financial liabilities. The amounts presented in the financial statements have been rounded to the nearest dollar.

### (b) Going Concern

The ability of the entity to continue as a going concern is principally dependent upon the company's ability to receive sufficient cash flow proceeds from fundraising, events and grants to meet operational obligations as and when they fall due and payable. The entity has a deficit of \$287,662 for the year ending 31 December 2019 (2018: \$97,193) and operating cash outflows of \$182,409 (2018: \$66,107). The current year deficit includes a significant once-off transaction being an accounting loss of \$147,031 related to the disposal of Rose Cottage. The current year results also include non-cash expenses of \$16,612 related to depreciation, \$10,300 related to a write-off of a sundry debtor and a net non-cash impact of \$14,895 as a result of the adoption of AASB 16: Leases. In addition, the entity has significantly reduced its debt in comparison to prior year with the following debt reductions included in operating cash outflows:

- Repayment of Cystic Fibrosis Australia Levies \$39,699
- Repayment of debt to ATO \$17,874
- Repayment of other long outstanding creditors amounting to \$30,050

As a result, the company has improved its working capital position during the period from a net current liability position at 31 December 2018 of \$197,382 to a net current asset position of \$56,339 at 31 December 2019. Furthermore, the entity has taken steps during the period to reduce overhead costs such as employee benefits expense and to increase the efficiency of fundraising processes through use of the Company's Salesforce platform rather than external fundraising platforms. The entity has reduced staff numbers from 8.2 Full Time Equivalent (FTE) to 6.5 FTE.

Based on the factors outlined above and a result of the ongoing support from government departments, the continued support of major donors and the anticipated success of fundraising activities and events, the directors believe the going concern basis of preparation is appropriate, and accordingly have prepared the financial report on this basis. The going concern basis presumes that funds will be available to finance future operations and that the realisation of assets and liabilities will occur in the normal course of business.

Should the entity be unable to continue as a going concern, it may be required to realise its assets and extinguish its liabilities other than in the ordinary course of business, and at amounts that differ from those stated in the financial statements. This financial report does not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts or classification of liabilities and appropriate disclosures that may be necessary should the entity be unable to continue as a going concern.

### **(c) Revenue**

The company recognises revenue as follows:

#### *Revenue from contracts with customers*

Revenue is recognised at an amount that reflects the consideration to which the company is expected to be entitled in exchange for transferring goods or services to a customer. For each contract with a customer, the company: identifies the contract with a customer; identifies the performance obligations in the contract; determines the transaction price which takes into account estimates of variable consideration and the time value of money; allocates the transaction price to the separate performance obligations on the basis of the relative stand-alone selling price of each distinct good or service to be delivered; and recognises revenue when or as each performance obligation is satisfied in a manner that depicts the transfer to the customer of the goods or services promised.

Variable consideration within the transaction price, if any, reflects concessions provided to the customer such as discounts, rebates and refunds, any potential bonuses receivable from the customer and any other contingent events. Such estimates are determined using either the 'expected value' or 'most likely amount' method. The measurement of variable consideration is subject to a constraining principle whereby revenue will only be recognised to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur. The measurement constraint continues until the uncertainty associated with the variable consideration is subsequently resolved. Amounts received that are subject to the constraining principle are recognised as a refund liability.

#### *Sales revenue*

Events, fundraising and raffles are recognised when received or receivable.

#### *Donations*

Donations are recognised at the time the pledge is made

#### *Grants*

Grant revenue is recognised in profit or loss when the company satisfies the performance obligations stated within the funding agreements.

If conditions are attached to the grant which must be satisfied before the company is eligible to retain the contribution, the grant will be recognised in the statement of financial position as a liability until those conditions are satisfied.

#### *Interest*

Interest revenue is recognised as interest accrues using the effective interest method. This is a method of calculating the amortised cost of a financial asset and allocating the interest income over the relevant period using the effective interest rate, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the net carrying amount of the financial asset.

# NOTES TO THE FINANCIAL STATEMENTS

---

## *Other revenue*

Other revenue is recognised when it is received or when the right to receive payment is established. Cystic Fibrosis Queensland Ltd receives non-reciprocal contributions of assets from the government and other parties for zero or a nominal value. These assets are recognised at fair value on the date of acquisition in the statement of financial position, with a corresponding amount of income recognised in the statement of profit or loss and other comprehensive income.

## *Volunteer services*

The company has elected to recognise volunteer services as either revenue or other form of contribution received. As such, any related consumption or capitalisation of such resources received is also recognised.

All revenue is stated net of the amount of goods and services tax (GST).

## **Income Tax**

No provision for income tax has been raised as the company is exempt from income tax under Division 50 of the Income Tax Assessment Act 1997.

### **(d) Employee Benefits Short-term employee benefits**

Provision is made for the Company's obligation for short-term employee benefits. Short-term employee benefits are benefits (other than termination benefits) that are expected to be settled wholly within 12 months after the end of the annual reporting period in which the employees render the related service, including wages and salaries. Short-term employee benefits are measured at the (undiscounted) amounts expected to be paid when the obligation is settled.

The company's obligations for short-term employee benefits such as wages and salaries are recognised as a part of current trade and other payables in the statement of financial position.

### **(e) Cash and Cash Equivalents**

Cash and cash equivalents include cash on hand, deposits held at call with banks, other short-term highly liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within short-term borrowings in current liabilities in the statement of financial position.

### **(f) Property, Plant and Equipment**

Each class of property, plant and equipment is carried at cost or fair value as indicated, less, where applicable, accumulated depreciation and any impairment losses.

#### **Property**

Freehold land and buildings are shown at their fair value based on periodic, but at least triennial, valuations by external independent valuers, less subsequent depreciation for buildings.

In periods when the freehold land and buildings are not subject to an independent valuation, the directors conduct directors' valuations to ensure the carrying amount for the land and buildings is not materially different to the fair value.

Increases in the carrying amount arising on revaluation of land and buildings are recognised in other comprehensive income and accumulated in the revaluation surplus in equity. Revaluation decreases that offset previous increases of the same class of assets shall be recognised in other comprehensive

income under the heading of revaluation surplus. All other decreases are recognised in the statement of comprehensive income.

Any accumulated depreciation at the date of the revaluation is eliminated against the gross carrying amount of the asset and the net amount is restated to the revalued amount of the asset.

### **Plant and equipment**

Plant and equipment are measured on the cost basis and are therefore carried at cost less accumulated depreciation and any accumulated impairment losses. In the event the carrying amount of plant and equipment is greater than its estimated recoverable amount, the carrying amount is written down immediately to its estimated recoverable amount and impairment losses are recognised either in profit or loss or as a revaluation decrease if the impairment losses relate to a revalued asset. A formal assessment of recoverable amount is made when impairment indicators are present

Plant and equipment that have been contributed at no cost, or for nominal cost, are valued and recognised at the fair value of the asset at the date it is acquired.

### **Depreciation**

The depreciable amount of all fixed assets, including buildings and capitalised lease assets but excluding freehold land, is depreciated on a straight-line basis or diminishing value basis over the asset's useful life to the company commencing from the time the asset is held ready for use. Leasehold improvements are depreciated over the shorter of either the unexpired period of the lease or the estimated useful lives of the improvements. Assets purchased with use of grant funds are fully depreciated in the year of purchase.

The depreciation rates used for each class of depreciable assets are:

- Buildings 4.00% (Straight line)
- Furniture, Fixtures and Fittings 7.00 – 66.67% (Diminishing value)
- Motor Vehicles 22.50% (Diminishing value)
- Rental Equipment 12.00- 50.00% (Diminishing value)

The assets' residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period.

### **(g) Right-of-use assets**

A right-of-use asset is recognised at the commencement date of a lease. The right-of-use asset is measured at cost, which comprises the initial amount of the lease liability, adjusted for, as applicable, any lease payments made at or before the commencement date net of any lease incentives received, any initial direct costs incurred, and, except where included in the cost of inventories, an estimate of costs expected to be incurred for dismantling and removing the underlying asset, and restoring the site or asset.

Right-of-use assets are depreciated on a straight-line basis over the unexpired period of the lease or the estimated useful life of the asset, whichever is the shorter. Where the company expects to obtain ownership of the leased asset at the end of the lease term, the depreciation is over its estimated useful life. Right-of use assets are subject to impairment or adjusted for any remeasurement of lease liabilities.

The company has elected not to recognise a right-of-use asset and corresponding lease liability for short-term leases with terms of 12 months or less and leases of low-value assets. Lease payments on these assets are expensed to profit or loss as incurred.

# NOTES TO THE FINANCIAL STATEMENTS

---

## (h) Financial Instruments

### Initial recognition and measurement

Financial assets and financial liabilities are recognised when the company becomes a party to the contractual provisions to the instrument. For financial assets, this is equivalent to the date that the company commits itself to either purchase or sell the asset (i.e. trade date accounting is adopted).

Financial instruments (except for trade receivables) are initially measured at fair value plus transactions costs, except where the instrument is classified “at fair value through profit or loss” in which case transaction costs are recognised immediately as expenses in profit or loss.

Trade receivables are initially measured at the transaction price if the trade receivables do not contain significant financing component or if the practical expedient was applied as specified in AASB 15.63.

### Classification and subsequent measurement

#### *Financial assets*

Financial assets are subsequently measured at:

- amortised cost;
- fair value through profit and loss on the basis of the two primary criteria, being:
  - the contractual cash flow characteristics of the financial asset; and
  - the business model for managing the financial assets.

A financial asset is subsequently measured at amortised cost when it meets the following conditions:

- the financial asset is managed solely to collect contractual cash flows; and
- the contractual terms within the financial asset give rise to cash flows that are solely payments of principal and interest on the principal amount outstanding on specified dates.

By default, all other financial assets that do not meet the conditions of amortised cost and the fair value through other comprehensive income's measurement condition are subsequently measured at fair value through profit and loss.

#### *Financial liabilities*

Financial liabilities are subsequently measured at:

- amortised cost; or
- fair value through profit and loss.

A financial liability is measured at fair value through profit and loss if the financial liability is:

- a contingent consideration of an acquirer in a business combination to which AASB 3 applies;
- held for trading; or
- initially designated as at fair value through profit or loss.

All other financial liabilities are subsequently measured at amortised cost using the effective interest method.

The effective interest method is a method of calculating the amortised cost of a debt instrument and of allocating interest expense in profit or loss over the relevant period. The effective interest rate is the internal rate of return of the financial asset or liability. That is, it is the rate that exactly discounts the estimated future cash flows through the expected life of the instrument to the net carrying amount at initial recognition.

## Derecognition

Derecognition refers to the removal of a previously recognised financial asset or financial liability from the statement of financial position.

### *Derecognition of financial assets*

A financial asset is derecognised when the holder's contractual rights to its cash flows expires, or the asset is transferred in such a way that all the risks and rewards of ownership are substantially transferred.

All of the following criteria need to be satisfied for derecognition of a financial asset:

- the right to receive cash flows from the asset has expired or been transferred;
- all risk and rewards of ownership of the asset have been substantially transferred; and
- the entity no longer controls the asset (i.e. it has no practical ability to make unilateral decisions to sell the asset to a third party).

On derecognition of a financial asset measured at amortised cost, the difference between the asset's carrying amount and the sum of the consideration received and receivable is recognised in profit or loss.

On derecognition of a debt instrument classified as fair value through other comprehensive income, the cumulative gain or loss previously accumulated in the investment revaluation reserve is reclassified to profit or loss.

On derecognition of an investment in equity which was elected to be classified under fair value through other comprehensive income, the cumulative gain or loss previously accumulated in the investments revaluation reserve is not reclassified to profit or loss, but is transferred to retained earnings.

### *Derecognition of financial liabilities*

A liability is derecognised when it is extinguished (i.e. when the obligation in the contract is discharged, cancelled or expires). An exchange of an existing financial liability for a new one with substantially modified terms, or a substantial modification to the terms of a financial liability, is treated as an extinguishment of the existing liability and recognition of a new financial liability. The difference between the carrying amount of the financial liability derecognised and the consideration paid and payable, including any non-cash assets transferred or liabilities assumed, is recognised in profit or loss.

## Impairment

The entity recognises a loss allowance for expected credit losses on:

- financial assets that are measured at amortised cost or fair value through other comprehensive income.

Expected credit losses are the probability-weighted estimate of credit losses over the expected life of a financial instrument. A credit loss is the difference between all contractual cash flows that are due and all cash flows expected to be received, all discounted at the original effective interest rate of the financial instrument.

The entity used the following approach to impairment, as applicable under AASB 9:

- the simplified approach.

### *Simplified approach*

The simplified approach does not require tracking of changes in credit risk in every reporting period, but instead requires the recognition of lifetime expected credit loss at all times.

# NOTES TO THE FINANCIAL STATEMENTS

---

This approach is applicable to:

- trade receivables or contract assets that result from transactions that are within the scope of AASB 15, that contain a significant financing component; and
- lease receivables.

In measuring the expected credit loss, a provision matrix for trade receivables was used taking into consideration various data to get to an expected credit loss (i.e. diversity of its customer base, appropriate groupings of its historical loss experience, etc).

## **Recognition of expected credit losses in financial statements**

At each reporting date, the entity recognised the movement in the loss allowance as an impairment gain or loss in the statement of profit or loss and other comprehensive income.

The carrying amount of financial assets measured at amortised cost includes the loss allowance relating to that asset.

Assets measured at fair value through other comprehensive income are recognised at fair value with changes in fair value recognised in other comprehensive income. An amount in relation to change in credit risk is transferred from other comprehensive income to profit or loss at every reporting period.

For financial assets that are unrecognised (eg loan commitments yet to be drawn, financial guarantees), a provision for loss allowance is created in the statement of financial position to recognise the loss allowance.

## **(i) Lease liabilities**

A lease liability is recognised at the commencement date of a lease. The lease liability is initially recognised at the present value of the lease payments to be made over the term of the lease, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the company's incremental borrowing rate. Lease payments comprise of fixed payments less any lease incentives receivable, variable lease payments that depend on an index or a rate, amounts expected to be paid under residual value guarantees, exercise price of a purchase option when the exercise of the option is reasonably certain to occur, and any anticipated termination penalties. The variable lease payments that do not depend on an index or a rate are expensed in the period in which they are incurred.

Lease liabilities are measured at amortised cost using the effective interest method. The carrying amounts are remeasured if there is a change in the following: future lease payments arising from a change in an index or a rate used; residual guarantee; lease term; certainty of a purchase option and termination penalties. When a lease liability is remeasured, an adjustment is made to the corresponding right-of-use asset, or to profit or loss if the carrying amount of the right-of-use asset is fully written down.

## **(j) Goods and Services Tax (GST)**

Revenue, expenses and assets are recognised net of the amount of goods and services tax (GST), except where the amount of GST incurred is not recoverable from the Australian Taxation Office (ATO). In these circumstances the GST is recognised as part of the cost of acquisition of the asset or as part of an item of the expense. Receivables and payables in the statement of financial position are shown inclusive of GST.

Cash flows are presented in the statement of cash flows on a gross basis except for the GST component of investing and financing activities, which are disclosed as operating cash flows.

### **(k) Comparative Amounts**

Where required by Accounting Standards, comparative figures have been adjusted to conform with changes in presentation for the current financial year.

### **(l) New or amended Accounting Standards and Interpretations adopted**

The company has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

#### *AASB 15 Revenue from Contracts with Customers*

The company has adopted AASB 15 from 1 January 2019. The standard provides a single comprehensive model for revenue recognition. The core principle of the standard is that an entity shall recognise revenue to depict the transfer of promised goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard introduced a new contract-based revenue recognition model with a measurement approach that is based on an allocation of the transaction price.

This is described further in the accounting policies below. Credit risk is presented separately as an expense rather than adjusted against revenue. Contracts with customers are presented in an entity's statement of financial position as a contract liability, a contract asset, or a receivable, depending on the relationship between the entity's performance and the customer's payment. Customer acquisition costs and costs to fulfil a contract can, subject to certain criteria, be capitalised as an asset and amortised over the contract period.

#### *AASB 16 Leases*

The company has adopted AASB 16 from 1 January 2019. The standard replaces AASB 117 'Leases' and for lessees eliminates the classifications of operating leases and finance leases. Except for short-term leases and leases of low-value assets, right-of-use assets and corresponding lease liabilities are recognised in the statement of financial position. Straight-line operating lease expense recognition is replaced with a depreciation charge for the right-of-use assets (included in operating costs) and an interest expense on the recognised lease liabilities (included in finance costs). In the earlier periods of the lease, the expenses associated with the lease under AASB 16 will be higher when compared to lease expenses under AASB 117. However, EBITDA (Earnings Before Interest, Tax, Depreciation and Amortisation) results improve as the operating expense is now replaced by interest expense and depreciation in profit or loss. For classification within the statement of cash flows, the interest portion is disclosed in operating activities and the principal portion of the lease payments are separately disclosed in financing activities. For lessor accounting, the standard does not substantially change how a lessor accounts for leases.

The impact on the financial performance and position of the consolidated entity from the adoption of this Accounting Standard is detailed below.

# NOTES TO THE FINANCIAL STATEMENTS

---

## *AASB 1058 Income of Not-for-Profit Entities*

The company has adopted AASB 1058 from 1 January 2019. The standard replaces AASB 1004 'Contributions' in respect to income recognition requirements for not-for-profit entities. The timing of income recognition under AASB 1058 is dependent upon whether the transaction gives rise to a liability or other performance obligation at the time of receipt. Income under the standard is recognised where: an asset is received in a transaction, such as by way of grant, bequest or donation; there has either been no consideration transferred, or the consideration paid is significantly less than the asset's fair value; and where the intention is to principally enable the entity to further its objectives. For transfers of financial assets to the entity which enable it to acquire or construct a recognisable non-financial asset, the entity must recognise a liability amounting to the excess of the fair value of the transfer received over any related amounts recognised. Related amounts recognised may relate to contributions by owners, AASB 15 revenue or contract liability recognised, lease liabilities in accordance with AASB 16, financial instruments in accordance with AASB 9, or provisions in accordance with AASB 137. The liability is brought to account as income over the period in which the entity satisfies its performance obligation. If the transaction does not enable the entity to acquire or construct a recognisable non-financial asset to be controlled by the entity, then any excess of the initial carrying amount of the recognised asset over the related amounts is recognised as income immediately. Where the fair value of volunteer services received can be measured, a private sector not-for-profit entity can elect to recognise the value of those services as an asset where asset recognition criteria are met or otherwise recognise the value as an expense.

## *Impact of adoption*

AASB 15 and AASB 1058 were adopted using the modified retrospective approach and as such comparatives have not been restated. There was no impact on opening retained surplus as at 1 January 2019.

AASB 16 was adopted using the modified retrospective approach and as such the comparatives have not been restated. The company has elected to apply the following transition practical expedients:

- To exclude initial direct costs from the measurement of right-of-use assets at the date of initial application;
- To exclude lessee arrangements with a short remaining term from date of initial application or leases assessed as low value;
- Use of a single discount rate for the portfolio of leases with reasonably similar characteristics;
- Use of hindsight with regards to determination of the lease term.

The impact of adoption on opening retained profits as at 1 January 2019 was as follows:

	1-Jan 2019
Operating lease commitments as at 1 January 2019 (AASB 117)	98,039
Operating lease commitments discount based on the weighted average incremental borrowing rate of 4.92% (AASB 16)	(27,931)
Add: Optional extension periods not recognised at 31 December 2018	165,703
Right-of-use assets (AASB 16)	235,811
Lease liabilities - current (AASB 16)	(22,999)
Lease liabilities - non-current (AASB 16)	(212,812)
Reduction in opening retained surplus as at 1 January 2019	-

## 2. Critical Accounting Estimates and Judgements

### (a) Key Estimates - Employee benefits

As described in the accounting policies, short-term employee benefits are measured at the (undiscounted) amounts expected to be paid when the obligation is settled.

### (b) Key Estimates - Lease term

The lease term is a significant component in the measurement of both the right-of-use asset and lease liability. Judgement is exercised in determining whether there is reasonable certainty that an option to extend the lease or purchase the underlying asset will be exercised, or an option to terminate the lease will not be exercised, when ascertaining the periods to be included in the lease term. In determining the lease term, all facts and circumstances that create an economical incentive to exercise an extension option, or not to exercise a termination option, are considered at the lease commencement date. Factors considered may include the importance of the asset to the company's operations; comparison of terms and conditions to prevailing market rates; incurrence of significant penalties; existence of significant leasehold improvements; and the costs and disruption to replace the asset. The consolidated entity reassesses whether it is reasonably certain to exercise an extension option, or not exercise a termination option, if there is a significant event or significant change in circumstances.

### (c) Key Estimates - Incremental borrowing rate

Where the interest rate implicit in a lease cannot be readily determined, an incremental borrowing rate is estimated to discount future lease payments to measure the present value of the lease liability at the lease commencement date. Such a rate is based on what the company estimates it would have to pay a third party to borrow the funds necessary to obtain an asset of a similar value to the right-of-use asset, with similar terms, security and economic environment.

The company has determined the incremental borrowing rate to be 4.92%.

# NOTES TO THE FINANCIAL STATEMENTS

<b>Note 3:</b>	<b>2019</b>	<b>2018</b>
<b>Revenue and Other Income</b>	<b>\$</b>	<b>\$</b>
<i>Revenue from contracts with customers</i>		
Bookshop / Thrift shop income	204,570	187,961
Events income	37,575	56,599
<b>TOTAL</b>	<b>242,145</b>	<b>244,560</b>
<i>Other Revenue</i>		
Contributions received in-kind	494,614	578,685
Interest received	16,519	56
Other grant income	117,272	140,671
Other income	5,358	8,603
Queensland health supporting funding	176,375	173,613
<b>TOTAL</b>	<b>242,145</b>	<b>244,560</b>

Within the revenues noted above, Cystic Fibrosis Queensland Ltd has received a total of \$369,237 (2018: \$395,929) in cash donations. During the year, the Company recognised \$242,145 of products and services transferred to customers at a point in time.

<b>Note 4:</b>	<b>2019</b>	<b>2018</b>
<b>Expenses</b>	<b>\$</b>	<b>\$</b>
The result for the year was derived after charging / (crediting) the following items:		
<i>Finance Costs</i>		
Interest - bank	3,507	17,582
Leases interest expense	20,355	-
<b>TOTAL</b>	<b>23,862</b>	<b>17,582</b>
Amortisation of right-of-use assets	63,705	-
Defined contribution superannuation expense	46,154	53,497
Depreciation	16,612	16,434
Write-off of receivables	10,300	-

<b>Note 5: Cash and cash equivalents</b>	<b>2019</b>	<b>2018</b>
	<b>\$</b>	<b>\$</b>
Cash on hand	545	450
Cash at bank	193,490	-
<b>TOTAL</b>	<b>194,035</b>	<b>450</b>

<b>Note 6: Trade and other receivables</b>	<b>2019</b>	<b>2018</b>
	<b>\$</b>	<b>\$</b>
<b>CURRENT</b>		
Trade receivables	5,720	7,877
Other receivables	-	10,299
<b>TOTAL</b>	<b>5,720</b>	<b>18,176</b>
<b>NON-CURRENT</b>		
Deposits	8,800	8,800
<b>TOTAL</b>	<b>8,800</b>	<b>8,800</b>

<b>Note 7: Inventories</b>	<b>2019</b>	<b>2018</b>
	<b>\$</b>	<b>\$</b>
Merchandise - at cost	-	6,010

<b>Note 8: Other assets</b>	<b>2019</b>	<b>2018</b>
	<b>\$</b>	<b>\$</b>
Prepayments	13,102	6,016

<b>Note 9: Property, plant and equipment</b>	<b>2019</b>	<b>2018</b>
	<b>\$</b>	<b>\$</b>
<i>LAND AND BUILDINGS</i>		
Rose Cottage		
At independent valuation	-	595,000
Less accumulated depreciation	-	(1,888)
Total Buildings	-	593,112
<b>Total land and buildings</b>	<b>-</b>	<b>593,112</b>
<i>PLANT AND EQUIPMENT</i>		
Furniture, fixtures and fittings at cost	-	4,761
Less accumulated depreciation	-	(4,761)
Total furniture, fixtures and fittings	-	-
Rental equipment at cost	-	90,817
Less accumulated depreciation	-	(90,817)
Total rental equipment	-	-
Total plant and equipment	-	-
<b>Total property, plant and equipment</b>	<b>-</b>	<b>593,112</b>

The company's assets are fully depreciated for accounting purposes and have been written off. The company maintains an asset register for these assets which is regularly updated.

# NOTES TO THE FINANCIAL STATEMENTS

## Note 9: Property, plant and equipment (continued)

Movement in the carrying amounts for each class of property, plant and equipment between the beginning and the end of the current financial year:

	Land and buildings	Furniture, fixtures and fittings	Rental equipment	Total
<b>2018</b>				
Balance at the beginning of the year	446,200	-	-	446,200
Additions at cost	-	-	-	-
Disposals	-	-	-	-
Revaluations	163,346	-	-	163,346
Depreciation expense	(16,434)	-	-	(16,434)
Carrying amount at the end of the year	593,112	-	-	593,112
<b>2019</b>				
Balance at the beginning of the year	593,112	-	-	593,112
Additions at cost	-	-	-	-
Disposals	(576,500)	-	-	(576,500)
Revaluations	-	-	-	-
Depreciation expense	(16,612)	-	-	(16,612)
Carrying amount at the end of the year	-	-	-	-

Note 10: Right-of-use assets	2019 \$	2018 \$
Land and buildings - right-of-use	538,227	-
Less: Accumulated depreciation	(63,705)	-
<b>TOTAL</b>	<b>474,522</b>	<b>-</b>

Additions to the right-of-use assets during the year were \$538,227. The company leases land and buildings for its head office and bookshop under agreements of between three to five years with options to extend. The leases have fixed rent escalation clauses.

Note 11: Trade and other payables CURRENT	2019 \$	2018 \$
Trade payables	39,055	122,341
BAS Payable	7,506	21,813
<b>TOTAL</b>	<b>46,561</b>	<b>144,154</b>

<b>Note 12: Financial liabilities</b>	<b>2019</b>	<b>2018</b>
	<b>\$</b>	<b>\$</b>
<i>Secured liabilities:</i>		
Overdraft Facility	-	4,614
<i>Unsecured liabilities:</i>		
Credit cards	2,003	2,053
<b>TOTAL</b>	<b>2,003</b>	<b>6,668</b>

<b>Note 13: Lease liabilities</b>	<b>2019</b>	<b>2018</b>
<b>CURRENT</b>	<b>\$</b>	<b>\$</b>
<i>Lease liability</i>	66,624	-
<b>NON-CURRENT</b>		
<i>Lease liability</i>	422,793	-

<b>Note 14: Employee benefits</b>	<b>2019</b>	<b>2018</b>
<b>CURRENT</b>	<b>\$</b>	<b>\$</b>
<i>Provision for annual leave</i>	20,523	30,686

<b>Note 15: Income in advance</b>	<b>2019</b>	<b>2018</b>
<b>CURRENT</b>	<b>\$</b>	<b>\$</b>
<i>Deferred income and unexpended grants</i>	20,807	46,526

<b>Note 16: Capital and Leasing Commitments</b>	<b>2019</b>	<b>2018</b>
<b>Operating Lease Commitments</b>	<b>\$</b>	<b>\$</b>
Payable minimum lease payments:		
Not later than 12 months	-	33,959
Between 12 months and 5 years	-	64,080
<b>TOTAL</b>	<b>-</b>	<b>98,039</b>

#### **Note 17: Contingent liabilities**

The Company had no contingent liabilities as at 31 December 2019 and 31 December 2018.

#### **Note 18: Reserves**

The asset revaluation reserve records revaluations of land and buildings

# NOTES TO THE FINANCIAL STATEMENTS

## Note 19: Capital Management

The entity's capital consists of financial liabilities supported by financial assets. Management effectively manages the entity's capital by assessing the entity's financial risks and responding to changes in these risks and in the market. These responses may include the consideration of debt levels. There have been no changes to the strategy adopted by Management to control the capital of the entity since previous year.

## Note 20: Key Management Personnel Disclosures

The totals of remuneration paid to the key management personnel of Cystic Fibrosis Queensland Ltd during the year are as follows:

Key management personnel	2019 \$	2018 \$
	163,699	161,053

## Note 21: Members' Guarantee

The Company is incorporated under the Corporations Act 2001, but now governed by Australian Charities and Not-for-profits Commission Act 2012 and is a Company limited by guarantee. If the Company is wound up, the constitution states that each Director is required to contribute a maximum of \$1 each towards meeting any outstanding's and obligations of the Company.

## Note 22: Remuneration of Auditors

Remuneration of the auditor of the Company for:

- Audit of the financial statements	12,200	11,850
Payment for other non-audit services including:		
- Bookkeeping services	26,208	27,745
- Additional accounting services	4,653	2,000
- AASB 16 Leases calculation	600	0
Total cost of other non-audit services	31,461	29,745

## Note 23: Events Occurring after the Reporting Date

No matters or circumstances have arisen since the end of the financial year which significantly affected or may significantly affect the operations of the Company, the results of those operations, or the state of affairs of the Company in future financial years.

## Note 24: Fair value measurement

The company measures its land and buildings at fair value on a recurring basis after initial recognition. The company does not measure any liabilities at fair value on a recurring basis and has no assets or liabilities that are measured at fair value on a non-recurring basis.

**Note 25: Company Details**

The registered and principal place of business is:

Cystic Fibrosis Queensland Ltd

30 Sylvan Road

TOOWONG QLD 4066



# DIRECTORS' DECLARATION

In accordance with a resolution of the directors of Cystic Fibrosis Queensland Ltd, the directors declare that:

1. The financial statements and notes, asset out in pages 8 to 25, satisfy the requirements of the Australian Charities and Not-for-Profits Commissions Act 2012 and:
2. there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

This declaration is signed in accordance with subsection 60.15(2) of the Australian Charities and Not-for-Profit Commission Regulation 2013.



M Walker  
Director  
20/03/20



K. L. Colyer  
Director  
20/03/20

GRANTS



\$117,272

BOOKSHOP



\$204,570

GOVERNMENT



\$176,375

**TOTAL REVENUE: \$1,467,875**

FUNDRAISING



\$548,708

MEMBERSHIP



\$5,385

IN-KIND



\$415,592

# REVENUE AND EXPENDITURE FOR 2019

SUPPORT, SERVICES AND ADVOCACY



\$515,929

INVESTED FUNDS



\$150,000

ADMINISTRATION



\$359,512

**TOTAL EXPENDITURE: \$1,467,875**

CF CLINICS



\$26,004

RESEARCH



\$31,412

OPERATIONS



\$385,018



WHILE WE WAIT FOR A CURE,  
WE CONTINUE TO FOCUS ON  
MEMBER WELLNESS IN A BID  
TO REDUCE FREQUENCY AND  
DURATION OF HOSPITAL STAY.

# INDEPENDENT AUDITOR'S REPORT

## Qualified Opinion

We have audited the financial report of Cystic Fibrosis Queensland Ltd (“the Company”) which comprises the statement of financial position as at 31 December 2019, the statement of profit or loss and other comprehensive income, the statement of changes in equity and the statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies, and the directors’ declaration.

In our opinion, except for the possible effects of the matters described in the Basis for Qualified Opinion paragraph below, the accompanying financial report of the Company is in accordance with Division 60 of the Australian Charities and Not-for-profits Commission Act 2012, including:

- a) giving a true and fair view of the Company’s financial position as at 31 December 2019 and of its financial performance and cash flows for the year then ended; and
- b) complying with Australian Accounting Standards – Reduced Disclosure Requirements and Division 60 of the Australian Charities and Not-for-profits Commission Regulation 2013.

## Basis for Qualified Opinion

Cash donations are a significant source of revenue for Cystic Fibrosis Queensland Ltd. The company has determined that it is impracticable to establish control over the collection of cash donation prior to entry into its financial records. Accordingly, as the evidence available to use regarding this revenue source was limited, our audit procedures with respect to cash donations has been restricted to the amounts recorded in the financial records. We therefore are unable to express an opinion on whether the recorded cash donations of Cystic Fibrosis Queensland Ltd are complete.

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the Auditor’s Responsibilities for the Audit of the Financial Report section of our report. We are independent of the Company in accordance with the auditor independence requirements of the Accounting Professional and Ethical Standards Board’s APES 110 Code of Ethics for Professional Accountants (“the Code”) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

## Responsibilities of Management and the Board for the Financial Report

Management is responsible for the preparation of the financial report that gives a true and fair view in accordance with the Australian Accounting Standards – Reduced Disclosure Requirements and the Australian Charities and Not-for-profits Commission Act 2012 and for such internal control as management determines is necessary to enable the preparation of the financial report that is free from material misstatement, whether due to fraud or error.

In preparing the financial report, management is responsible for assessing the Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

The Board is responsible for overseeing the Company’s financial reporting process.

## Auditor’s Responsibilities for the Audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that

includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.


As part of an audit in accordance with the Australian Auditing Standards, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
- Conclude on the appropriateness of the management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the Board regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the Board with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

HLB Mann Judd



Chartered Accountants Partner

A B Narayanan



Chartered Accountants Partner

Brisbane, Queensland  
18 March 2020



# NON-PROFIT SUPPORTS

SUPPORT OUR CAUSE

RAISING FUNDS  
AND  
AWARENESS.

# PARTNERSHIP

# 4

## BOUNCE 2 BREATHE - B2B



Of all the physical therapies people living with cystic fibrosis must endure, bouncing on a trampoline is the only one that is fun. Inspired by this we developed a trampoline fundraising program Bounce 2 Breathe (B2B). Mango Hill State School hosted a 65 Roses for Cystic Fibrosis May activation that saw Queensland Health Minister, Dr Steven Miles, jumping into action alongside more than 1000 students. In one day they successfully raised over \$17 000.

Thanks to our partnership with Urban Xtreme, next year schools and businesses will have the option of hosting a B2B on-site or holding an event at the adventure park.


## CEO KITCHEN - COOKING FOR A CAUSE



This year saw eight CEO Kitchen Chefs create cystic fibrosis-friendly dishes for our CEO Kitchen Judges Javier Codina (Chef de Cuisine and Co-owner MODA Restaurant) and Josue Lopez at MODA Portside. Raising funds and awareness for our cause, the collective effort of the CEO Kitchen Chefs raised more than \$45 000.00 for our cause.

Next year we are inviting you to all be the CEOs of your kitchen and to host a dinner party at your home, creating cystic fibrosis-friendly dishes.

The online fundraising platform will include recipes and tips from dieticians - further delivering on our mission to educate and raise awareness.



## THE ROSE CUP CHARITY GOLF DAY

Charity partners LJ Hooker Southport, LJ Hooker Nerang and RealEstate.com.au hosted our second Rose Cup Charity Golf Day at Arundel Hills Golf Course, Gold Coast with teams from LJ Hooker offices and local businesses. By providing marketing support with a website and registration portal, our partnership successfully raised over \$25 000 and is now part of our annual calendar of events.

Our supporters continue to shine; finding new and creative ways to raise money and awareness for our programs. Almost 90% of our essential funding comes from these community supporters.

From Darwin NT, to Longreach QLD, Maclean NSW, and everywhere in between, our community came out in force to set goals, raise funds and support advocacy for cystic fibrosis sufferers during 2019. Each unique event was created and supported by people with commitment and determination who hit golf balls, ran, swam, skipped, rattled tins, held dinners and sold roses for adults and children living with cystic fibrosis.

LJ HOOKER OFFICES ON THE GOLD COAST RAISED \$25,756 FOR CYSTIC FIBROSIS QUEENSLAND

## 65 ROSES FOR CYSTIC FIBROSIS

May remains our national month of awareness for cystic fibrosis. Cystic Fibrosis Queensland was proud to see an increase in advocacy, with regional councils of Mackay, Rockhampton, Emerald, Toowoomba and Sandgate joining Brisbane and Sandgate in promoting our national awareness campaign by illuminating landmarks and promoting our cause. Cystic Fibrosis Queensland also engaged members of Queensland and Northern Territory Parliament to champion the needs of Australians battling cystic fibrosis by wearing a Cystic Fibrosis 65 Roses Pin and raising awareness for cystic fibrosis within their electorate.

65 Roses for Cystic Fibrosis May fundraising activities remained consistent with previous years, raising over \$70 000 through an assortment of fundraising initiatives that saw rose tattooing on the Gold Coast, Body Waxing in Darwin and CrossFit Challenges on the Sunshine Coast. In 2019, Cystic Fibrosis Queensland was again supported by WAFEX through donated long stemmed roses for sale within our community. Rose sales could not be possible without our teams of volunteers who prepare long stemmed roses for our community fundraisers to sell. This year we extended our reach and our volunteers sold roses across the University of Queensland Pharmaceutical Campus, Toowoomba 65 Roses High Tea events and at community functions around Brisbane. Cystic Fibrosis Queensland looks forward to continued corporate growth for 65 Roses for Cystic Fibrosis, May, 2020.

# COMMUNITY FUNDRAISING

# 4

## Thank you 65 Roses Month of May fundraisers:

- Gymnastic Mackay
- Forest Lake Crafts Ladies
- Let's Dance Latin
- 65 Roses Challenges on Everyday Hero
- Queensland Lions Club Donations
- Cross Fit Caloundra with Stuart & Angela Anderson
- Wax The Boss With Nikki & Damian Telford
- Allied Health Redland Hospital
- University of Queensland Pharmaceutical Campus Ruby Yeh
- Ace of Wands Tattoo
- Sue Macdonald & Bianca Best
- Mosaic Christian Early Learning Centre

SOMEONE I LOVE  
NEEDS A CURE.





THE 65 ROSES STORY DATES BACK TO 1965 WHEN AN OBSERVANT FOUR YEAR OLD, HEARING THE NAME OF HIS DISEASE FOR THE FIRST TIME, PRONOUNCED CYSTIC FIBROSIS AS 65 ROSES. TODAY, 65 ROSES IS A TERM OFTEN USED BY YOUNG CHILDREN WITH CYSTIC FIBROSIS TO PRONOUNCE THE NAME OF THEIR DISEASE.

# COMMUNITY FUNDRAISING

# 4

## MAJOR APPEALS

Cystic Fibrosis Queensland launched two major appeals starting with the pre-tax appeal in April featuring pre-teen and teenager sisters from Western Australia who undergo their arduous cystic fibrosis treatment together, and discussed the impact cystic fibrosis has on their young lives. And at Christmas, we learned about the struggles of the Coleman family, who not only manage the complications of cystic fibrosis during the early childhood years of their daughter, but also the pressures of living in remote Queensland. Cystic Fibrosis Queensland called to support families like the Coleman, who have the additional isolating factors of experiencing admissions to cystic fibrosis centres, far away from home.

Donations from these two appeals totalled approximately \$70 000 vastly increasing from the results from the previous financial year. To support 65 Roses for Cystic Fibrosis, an inaugural 65 Roses Giving Day was held. The campaign focused on building online donor engagement through influencers and raised just over \$2 000.00



## MAJOR COMMUNITY FUNDRAISERS

### BLUESFEST WITH ALAN AND JENNY TUNKS

Ballina locals, Alan and Jenny Tunks approached the Byron Bay Bluesfest 23 years ago and sought for cystic fibrosis to be the event charity of choice and it has remained the signature festival raffle fundraiser. Alan and Jenny spend up to six months a year planning the fundraiser: they source guitars pro bono and arrange for the Bluesfest artists to sign, they recruit and train the cystic fibrosis volunteer army, roster the ticket sellers, manage the associated media, deal with the daily banking and personally deliver the winning prizes. Over the past 23 years, the Tunks have raised more than \$650 000.00 for our cause and in 2019 provided Cystic Fibrosis Queensland with a \$32 250.00 donation to support the programs delivered to Cystic Fibrosis Queensland members.

## **ROCKHAMPTON PANTHERS**

The Rockhampton Panthers AFC hosted their annual Cystic Fibrosis Awareness Round in July. To celebrate their 5th year of awareness and fundraising, the organisation hosted the inaugural CF Gala Ball. The Rockhampton community stepped up with an overwhelming response to support the event. The ball featured Australian Cricketer, Jemma Barsby, who shared her motivational journey as a professional cricketer, despite living with a chronic illness. The ball and awareness jersey auction was a huge success, raising over \$12 000 for Queenslanders living with cystic fibrosis.

## **MEGAN WALKER MINI MARATHON**

Rosemary Champion has been instrumental in the promotion of advocacy and fundraising for cystic fibrosis in Central West Queensland over the last 30 years. Margaret organises and has grown the annual Meagan Walker Mini Marathon, raising in excess of \$115 000. This widely popular event has achieved growth and longevity through the contributions and commitment of the local community. This is a testament to the relationships and impact Rosemary has developed in the Central West. The Meagan Walker Mini Marathon is a part of the social fabric of Longreach, combining schools, emergency response departments and businesses to come together for a common goal; increasing awareness and raising funds to provide research and support for those with cystic fibrosis. In 2019 The Megan Walker Mini Marathon raised over \$5 000 for Cystic Fibrosis Queensland and looks forward to a prosperous 2020.

## **TEAM CYSTIC FIBROSIS QUEENSLAND - NOOSA TRIATHLON**

For the fourth year running, Cystic Fibrosis Queensland has supported the IRONMAN Noosa Multisport Festival and Triathlon as a charity partner. Our team of 46 triathletes themselves to their physical limits while raising over \$46 000.00. Our team of Triathletes came from all over Queensland, with athletes joining us from Mt Isa and Mackay. In 2020, Cystic Fibrosis Queensland invites cystic fibrosis supporters from across Australia, to support all cystic fibrosis states and territories by joining Team Cystic Fibrosis on the fight to breathe. To date our triathletes have raised more than \$120 000 for our cause - their competitive spirit driving both their PBs and fundraising!

## **TAKING GREAT STRIDES FOR OUR COMMUNITY**

Great Strides continues to spread its footprint across Queensland and the Northern Territory. This year our inaugural Redcliffe twilight event raised over \$13 000.00 and will return next year to join the successful Gold Coast and biennial Darwin Great Strides activations. Cystic Fibrosis Queensland will take even bigger strides in 2020, with the introduction of Great Strides events in Brisbane and Cairns. Great Strides Gold Coast has raised an impressive \$63 000.00 over the past ten years.

# COMMUNITY FUNDRAISING

# 4



THE NOOSA TRIATHLON IS AN INTERNATIONALLY RENOWNED EVENT AND OUR CONTINUED PARTNERSHIP WITH THE FESTIVAL ALLOWS US TO INCREASE AWARENESS FOR CYSTIC FIBROSIS IN THE LOCAL SUNSHINE COAST COMMUNITY AND EXPAND OUR REACH ON A GLOBAL PLATFORM.



# COMMUNITY FUNDRAISING

# 4

---

## HEART FELT THANKS TO OUR KEY COMMUNITY FUNDRAISERS

- Fundraising Services Collectors
- Hunt for a Cure with Braden Lamb
- LJ Hooker Maclean Coast to Course
- Breathe Art Auction
- Rockhampton Panthers AFC
- Patricia Woodruff - Account One Finance
- Black Tie and Bubbles
- Brisbane Chili Festival
- The Bundaberg Wedding Spectacular
- Jamie Bell's Charity Ride
- Megan Walker Mini Marathon



IMPACT IN ACTION - RAISING FUNDS AND AWARENESS TO CHANGE LIVES

---

## CYSTIC FIBROSIS QUEENSLAND BOOKSHOP

In 2018, the Cystic Fibrosis Queensland Bookshop marked 10 years of operations at the Ryan's Road location, further cementing its influence as a part of the vibrant social fabric of the Nundah community. The Cystic Fibrosis Queensland Bookshop is the largest warehouse of quality second-hand books in Queensland. Donations from the State Library and Brisbane City Council Libraries, alongside our donations from the public, continue to supply us with a variety of genres and interests; we have a book for every taste and sensibility!

Our partnership with the Lord Mayors Charitable Trust ensures that 30% of the sale of Brisbane City Council Library books sold at the Cystic Fibrosis Queensland Bookshop is returned to council initiatives for the Brisbane community.

Volunteers and work-for-the-dole placements continue to be the staffing back bone of the shop and contribute 320 warehouse hours per month and 200 administrative hours, equating to a total savings of \$10 941 in salaries each month.

CF SMART has been embedded in to the volunteer and work-for-the-dole placement orientation. This further engages our volunteer team with our community and increases their knowledge about our cause.

EACH MAY WE CHALLENGE 65 BUSINESSES TO TAKE UP THE 65 ROSES MONTH OF MAY FUNDRAISING AND AWARENESS CAMPAIGN AND RAISE \$650



THE POWER OF GIVING,  
THE JOY OF RECEIVING AND  
THE VIRTUE OF GIVING THANKS.

# GRANTS AND MAJOR DONORS

# 4

Cystic Fibrosis Queensland receives support from a small group of philanthropic individuals and organisations which share our belief in our cause. The generosity demonstrated by these people enables Cystic Fibrosis Queensland to lighten the burden experienced by our members who are living with cystic fibrosis.

## THANK YOU TO OUR GRANT MAKERS

Our grantors make a valuable contribution, enabling us to deliver our programs and act on our mission of lives unaffected by cystic fibrosis:

- Aurizon Foundation
- Broncos Foundation
- Commonwealth Bank
- Colliers Charitable Fund
- Continenence Foundation
- Cory Charitable Foundation
- Merlin's Magic Wand Foundation
- Queensland Community Foundation
- Lord Mayors Charitable Trust
- Northgate Ward, Brisbane City Council
- Queensland Alliance
- Epic Assist Community Grant
- Vertex
- Department of Social Services
- Department of Queensland Health
- The William Angliss Charitable Fund
- The Courier-Mail Fund
- Slater and Gordon Community Fund

## IN-KIND AND PRO BONO SUPPORTERS OVER \$500

Thank you to our generous supporters who have provided assistance with products and services in support of our cause. From toys, theme park family passes to pro bono services from our corporate partners, these contributions have all made an impact to the lives of our members

- All-Purpose Transport
- Arrivederci Pizzeria
- Brisbane Lord Mayor's Charitable Trust
- Bundy Bullet
- BVN Architecture
- Cameron Lewis Construction
- Centurion
- Chroma Hair Design
- CNQ Freight
- Coorparoo Quilters Group
- Deep Grey Photography
- Good360
- Harlow Hot Yoga Newstead
- J & P Richards
- Lana Noir
- Libertine
- LJ Hooker Aspley | Chermside
- McCulloch Robertson
- Naples Pizzeria
- Noosa Rotary
- NQ Freighters
- Priceline Pharmacy
- QT Gold Coast
- Queensland Police Service
- Sheraton Grand
- Sofitel Brisbane
- Stephanie's
- Stone & Wood
- TAFE
- Tamex
- Terry White Chemist
- Treasury Brisbane
- Verve Portraits
- Village Roadshow Themeparks
- Wafex (DanielStean)
- Web and Warehouse

I AM WHAT A PERSON WITH AN  
INVISIBLE ILLNESS LOOKS LIKE



# GRANTS AND MAJOR DONORS

# 4

THANK YOU TO OUR DONORS WHO HAVE DUG DEEP AND GIVEN GENEROUSLY.

MAJOR DONORS OVER \$2 000

- Kim Colyer
- Glen Minnis

MAJOR DONORS OVER \$5 000

- Karen and Gavin Bird
- Naomi McQueen
- DruryFamily
- Lions Club of Mt Tambourine
- Michael White - Brackenridge Tavern
- L.R.Barnett

MAJOR DONORS OVER \$10 000

- Les Clarence

SERVICE CLUBS AND COMMUNITY GROUP DONORS

- DruryFamily
- Rotary Club of Auchenflower Wesley
- Lions Club of Burleigh Heads
- Australasian Order of the Old Bastards - Gold Coast
- Lions Club of Rosewood
- Lions Club of Ashgrove



THE GROWTH THAT WE HAVE SEEN THROUGH OUR OUTREACH AND AWARENESS CANNOT BE POSSIBLE WITHOUT THE HARD WORK AND DEDICATION OF OUR BOOKSHOP VOLUNTEERS.

# OUR PRIORITIES

# 4

JULY 2020 WILL BE OUR BIRTHDAY - CELEBRATING 60 YEARS OF PROVIDING SUPPORT, SERVICES AND HOPE TO PEOPLE FIGHTING CYSTIC FIBROSIS.

## IMPROVING SERVICE DELIVERY

Results from the 2019 Cystic Fibrosis Queensland Survey shape our business.

Working with Queensland Health to complement Government services - reducing frequency and duration of hospital stays.

## RURAL, REGIONAL AND REMOTE

Provide programs to meet the needs of members by addressing the financial, physical and emotional burden of the disease.

## CHANGING DEMOGRAPHIC

No longer a childhood disease. Today, there are more adults than children living with cystic fibrosis. Our programs must keep evolving to meet the needs of our members.

## PLANNING FOR OUR FUTURE

As the peak cystic fibrosis body, meeting members' needs today and into the future, we must be robust in nature and financially sustainable.

## ADVOCACY

Continue to be the voice for our community. While there is no cure for cystic fibrosis, education and knowledge about the disease and infection control has greatly improved outcomes.

## STAKEHOLDER ENGAGEMENT

Work alongside clinicians, researchers and the State and Territory members of our Federation to ensure that one day we will all lead lives unaffected by cystic fibrosis.



CYSTIC FIBROSIS AFFECTS EVERYONE DIFFERENTLY. PEOPLE HAVE TRADITIONALLY REFERRED TO CYSTIC FIBROSIS AS A LUNG DISEASE BECAUSE THAT'S THE MOST COMMONLY KNOWN CLINICAL MANIFESTATION OF ILLNESS. BUT FOR MOST OF THOSE WITH CYSTIC FIBROSIS, THE LUNGS ARE ONLY A PART OF IT, AND FOR SOME, NOT EVEN THE WORST PART.

# OUR DIAMOND JUBILEE

# 4

---

## 60 Years of providing support, services and hope to those fighting cystic fibrosis.

The Cystic Fibrosis Australia Federation that we know today started in July, 1960 in a small church hall in Annerley, Brisbane. We are proud of our achievements and even prouder of our members who continue to fight every day, just to breathe. Our team of talented and committed staff is focused on creating sustainable income streams to ensure we continue to support the increasing number of people living with cystic fibrosis. Cystic fibrosis affects everyone differently. People have traditionally referred to cystic fibrosis as a lung disease because that's the most commonly known clinical manifestation of illness. But for most of those with cystic fibrosis, the lungs are only a part of it, and for some, not even the worst part.

Cystic fibrosis is typically caused by a defective ion transport protein — the cystic fibrosis transmembrane conductance regulator protein, or CFTR. When the protein doesn't function properly, salt transport is dysfunctional, which is what causes cystic fibrosis mucus to be so thick. This means that the majority of cystic fibrosis disease resides in the organs and tissues surrounded by mucosal layers: the lungs, stomach, gastrointestinal tract, sinuses, pancreas, and liver. Cystic fibrosis disease goes further than that. Because of constant exposure to medications, it can also severely damage kidneys. Our programs continue to evolve to ensure we are meeting the needs of our changing demographic. Cystic fibrosis is no longer a childhood disease and Cystic Fibrosis Queensland will continue to reflect this change in our programs to better meet the needs of the growing number of adults now living with cystic fibrosis.

Relationships with the cystic fibrosis wards at the Queensland Children's Hospital, Mater Young Adults Health Clinic, and The Prince Charles Hospital remain important to the programs we deliver. We are an extension of Queensland Health services and while not funded by government, work tirelessly to complement the clinicians. Cystic Fibrosis Queensland will also continue to reach out to many of the smaller, regional clinics, which provide a crucial service to cystic fibrosis sufferers living some distance from Brisbane. The importance of adherence to health directives and infection control will remain at the forefront of our advocacy. Cystic Fibrosis Queensland is honoured to be the peak body in Queensland and the Northern Territory, which represents all cystic fibrosis sufferers, and we will continue the fight to breathe!

OUR PROGRAMS ARE REGULARLY RE-EVALUATED TO ENSURE WE ARE MEETING THE NEEDS OF OUR CHANGING DEMOGRAPHIC.



## OUR DIAMOND JUBILEE

In 2020, Cystic Fibrosis Queensland is celebrating its diamond jubilee, 60 years of providing support, services and hope to those fighting cystic fibrosis.

## DIAMOND JUBILEE DONORS CLUB

For our diamond jubilee, we wish to establish a perpetuity account, securing the long-term future of the organisation.

We are seeking 60 founding members to donate \$1 000 each to establish a \$60 000 perpetuity account. It is intended that this account will be added to over time but it is imperative that we get it off the ground with a solid start.

## BE PART OF THE JUBILEE CELEBRATIONS

Our diamond jubilee celebrations will occur throughout 2020 culminating in our Diamond Jubilee Cocktail Event, Friday, 12 March 2021 at The Greek Club, West End. We look forward to seeing you there.



# RECOGNISING OUR VOLUNTEERS

# 4

At Cystic Fibrosis Queensland, we believe that our volunteers are a part of the wider cystic fibrosis community. Each and every person who contributes to our cause donates their time and their individual skills to help us grow our impact in our community. We have dedicated volunteers who make our jobs just that little bit easier and add a lot of joy and colour to our lives.

Volunteering is not about money. Volunteering is about giving, contributing, and helping other individuals and the community at large. It is working with others to make a meaningful contribution to a better community. At Cystic Fibrosis Queensland our volunteers undertake all office and reception duties, they prepare and pack our Boredom Buster Bags for our weekly delivery to children in hospital and university students work on our marketing and social media campaigns. At our Bookshop in Nundah our volunteers stack shelves and provide front line retail customer service.

People volunteer with Cystic Fibrosis Queensland for an endless variety of reasons. Many people want to gain experience, acquire new skills, meet new people, or expand their network of contacts as a way to get a new job or start a career. Others just want to give back to their community, to help a friend or promote a worthwhile activity. Volunteering jobs are as rich and diverse as the people who volunteer.

We are always seeking to make sure that volunteering with Cystic Fibrosis Queensland is not only rewarding, but easy to do. Thanks to our pro bono partner FoundU, we launched an online platform which allows current and prospective volunteers to search and select shifts based on their interest and availability. All of the volunteers complete CFSMART as part of the registration process, raising their awareness of the cause that they are supporting.

**THANK YOU VOLUNTEERS. YOUR CONTRIBUTION EQUATES TO A SAVING OF ALMOST \$300 000.00 IN WAGES.**





**CYSTIC  
FIBROSIS**  
Queensland

# THANK YOU TO OUR SPONSORS

---



Collier Charitable Fund



Commonwealth Bank



DESIGN BY



Green Fox Studio

# CYSTIC FIBROSIS QUEENSLAND

---

## JOIN THE FIGHT TO BREATHE

- Become a Cystic Fibrosis Queensland Member
- Volunteer Your Time
- Make a Donation
- Leave a Gift in your Will
- In-memoriam Services
- Support an Event or Fundraising Activity
- Become a Corporate Partner
- 65 Roses Cystic Fibrosis Workplace Giving

### CONTACT US

+61 7 3359 8000

1800 670 990 (Outside Brisbane)

[www.cysticfibrosis.org.au](http://www.cysticfibrosis.org.au)

click on **Queensland** or the **Northern Territory**

[admin@cfqld.org.au](mailto:admin@cfqld.org.au)



2/30 Sylvan Road,  
Toowong, QLD, 4066  
PO Box 86 Toowong  
Business Hub, QLD, 4066  
ACN 010 549 6676  
ABN 97 010 549 67